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A B S T R A C T
Background
Anaemia is a global public health problem. Children under five years of age living in developing countries (mostly Africa and South-
East Asia) are highly affected. Although the causes for anaemia are multifactorial, malaria has been linked to anaemia in children living
in malaria-endemic areas. Administering intermittent preventive antimalarial treatment (IPT) to children might reduce anaemia, since
it could protect children from new Plasmodium parasite infection (the parasites that cause malaria) and allow their haemoglobin levels
to recover.
Objectives
To assess the effect of IPT for children with anaemia living in malaria-endemic areas.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, Cochrane Central of Controlled Trials (CENTRAL),
published in The Cochrane Library; MEDLINE; EMBASE; and LILACS. We also searched the World Health Organization (WHO)
International Clinical Trial Registry Platform and metaRegister of Controlled Trials (mRCT) for ongoing trials up to 4 December
2014.
Selection criteria
Randomized controlled trials (RCTs) evaluating the effect of IPT on children with anaemia.
Data collection and analysis
Two review authors independently extracted data and assessed risk of bias. We analysed data by conducting meta-analyses, stratifying
data according to whether participants received iron supplements or not. We used GRADE to assess the quality of evidence.
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Main results
Six trials with 3847 participants met our inclusion criteria. Trials were conducted in areas of low malaria endemicity (three trials), and
moderate to high endemicity (three trials). Four trials were in areas of seasonal malaria transmission. Iron was given to all children in
two trials, and evaluated in a factorial design in a further two trials.
IPT for children with anaemia probably has little or no effect on the proportion anaemic at 12 weeks follow-up (four trials, 2237
participants, (moderate quality evidence).
IPT in anaemic children probably increases the mean change in haemoglobin levels from baseline to follow-up at 12 weeks on average
by 0.32 g/dL (MD 0.32, 95% CI 0.19 to 0.45; four trials, 1672 participants, moderate quality evidence); and may improve haemoglobin
levels at 12 weeks (MD 0.35, 95% CI 0.06 to 0.64; four trials, 1672 participants, low quality evidence). For both of these outcomes,
subgroup analysis did not demonstrate a difference between children receiving iron and those that did not.
IPT for children with anaemia probably has little or no effect on mortality or hospital admissions at six months (three trials, 3160
participants moderate quality evidence). Subgroup analysis did not show a difference between those children receiving iron supplements
and those that did not.
Authors’ conclusions
Trials did show a small effect on average haemoglobin levels but this did not appear to translate into an effect on mortality and hospital
admissions. Three of the six trials were conducted in low endemicity areas where transmission is low and thus any protective effect is
likely to be modest.
P L A I N L A N G U A G E S U M M A R Y
Antimalarial drugs as a treatment of anaemia in children living in malaria-endemic areas.
Children living in malaria areas may develop severe anaemia, often caused by malaria infection, and this can cause death if not treated
properly. Intermittent preventive treatment (IPT) is a course of malaria treatment given regularly to these children in order to prevent
infection and malaria illness. It has been suggested that IPT could be used to treat children with anaemia in these areas. We aimed to
find all the studies looking at treating anaemic children with IPT in order to see what the overall effect is. We examined the evidence
available up to 4 December 2014.
We included six trials in this review, with a total number of 3847 participants. In all the trials, one group received IPT and the control
group received placebo. Three trials were done in low malaria endemicity areas and the other three in high endemicity areas. In some
trials, iron supplements were also given to children, which is also a treatment for anaemia, and we took this into consideration when
analysing the data.
Our results did not find that the number of children who died or were admitted to hospital was lower in the group receiving IPT,
irrespective of whether they received iron (moderate quality evidence); and there was no difference in the number of children with
anaemia at the end of follow-up (moderate quality evidence). Average haemoglobin levels were higher in the IPT group compared to the
placebo group, but the effect was modest (low quality evidence).
Although our results show that there are small benefits in haemoglobin levels when treating anaemic children with IPT, we did not
detect an effect on death or hospital admissions. However, three of the six included trials were conducted in low endemicity areas where
malaria transmission is low and thus any protective effect is likely to be modest.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Intermittent preventive treatment compared to placebo for children with anaemia
Patient or population: Children with anaemia
Settings: Malaria-endemic areas
Intervention: IPT (± iron and folic acid)
Comparison: Placebo (± iron and folic acid)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo IPT
Death or hospital admis-
sion
Follow up at 6 months
34 per 1000 31 per 1000
(24 to 38)
RR 0.9
(0.71 to 1.13)
3160
(3 trials)
⊕⊕⊕©
moderate1,2,3,4
Children with anaemia
(Hb < 11 g/ dL)
Follow up at 12 weeks
579 per 1000 561 per 1000
(510 to 620)
RR 0.97
(0.88 to 1.07)
2237
(4 trials)
⊕⊕⊕©
moderate2,5,6,7
M ean change in Hb from
baseline
Follow up: 12 weeks
The mean change ranged
across control groups f rom
0.32 to 5.4 g/ dL
The mean change in the in-
tervent ion groups was
0.32 g/ dL higher
(0.19 to 0.45 higher)
- 1672
(4 trials)
⊕⊕⊕©
moderate2,8,9,10
M ean Hb
Follow up at 12 weeks
The mean Hb concentra-
t ion ranged across control
groups f rom
9.91 to 10.7 g/ dL
The mean Hb concentrat ion
in the intervent ion groups
was
0.35 g/ dL higher
(0.06 to 0.64 higher)
- 1672
(4 trials)
⊕⊕©©
low8,9,10,11
* The basis for the assumed risk is the median control group risk across trials. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group
and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io; IPT: interm it tent prevent ive treatment; AL: artemether lumefantrine.3
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 No serious risk of bias: The largest trial was at low risk of bias. The two smaller trials were at high risk of attrit ion bias, but
exclusion of these trials does not change the result .
2 No serious inconsistency: Stat ist ical heterogeneity was low.
3 No serious indirectness: The three trials were conducted in the Gambia, Kenya and Malawi, one trial gave IPT (AL monthly)
to children discharged f rom hospital following severe malarial anaemia, and two trials gave IPT (SP monthly) to anaemic
children attending hospital, outpat ient clinics or recruited in the community. There was no signif icant result for subgroup
dif ferences between areas with high versus areas with low endemicity.
4 Downgraded by 1 for serious imprecision: The 95% CI around the absolute risk dif f erence is very narrow and excludes
clinically important ef fects. However, much larger trials would be necessary to fully exclude small benef its with IPT.
5 Downgraded by 1 for serious risk of bias: high risk of attrit ion bias for Bojang 2010 GMB and Desai 2003 KEN.
6 No serious indirectness: All the trials gave IPT (SP) monthly to anaemic children attending hospital, outpat ient clinics or
recruited in the community. There was no signif icant result for subgroup dif ferences between areas with high versus areas
with low endemicity.
7 No serious imprecision: No ef fect was seen and the meta-analysis is adequately powered to detect an ef fect.
8 No serious imprecision. A small ef fect was seen although this disappears when we removed trials at high risk of bias f rom
the analysis.
9 Downgraded by 1 for serious risk of bias: High risk for attrit ion bias for Bojang 2010 GMB and Desai 2003 KEN.
10 No serious indirectness: Three trials gave IPT (SP) monthly and one trial gave CQ weekly to anaemic children attending
hospital, outpat ient clinics or recruited in the community. There was no signif icant result for subgroup dif ferences between
areas with high versus areas with low endemicity.
11 Downgraded for serious inconsistency: Heterogeneity (I² stat ist ic = 76%; Chi² stat ist ic = 16.93; P = 0.002) is present. One
trial is an out lier (Desai 2003 KEN).
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B A C K G R O U N D
Description of the condition
Anaemia is a public health problem that affects people worldwide.
Between 1993 and 2005, an estimated 1.62 billion people world-
wide had anaemia, which corresponded to 24.8% of the world’s
population (WHO 2008). The reported global prevalence was
47.4% in children aged under five. Children in Africa and South-
East Asia carried the highest reported burden of anaemia: 67.6%
and 65.5% respectively (WHO2008). Causes of anaemia are mul-
tifactorial and include poor nutritional status, micronutrient defi-
ciencies (especially iron deficiency, but also vitamin A, vitamin B
and folic acid), intestinal helminth infection, HIV infection and
haemoglobinopathies (Calis 2008). However, malaria is probably
the most important cause of anaemia in malaria-endemic coun-
tries (Antony 2008; Balarajan 2011; Crawley 2004). Anaemia is
also more common in children from low-income and illiterate
families, compared to children coming fromwealthier households
(Balarajan 2011).
Malaria causes anaemia mainly by destruction of red blood cells
(haemolysis) (Looareesuwan 1987) but also by causing an increase
in the splenic pool of red blood cells and decreased production of
red blood cells (Crawley 2004; Phillips 1992). Acute loss of red
blood cells may lead to severe anaemia. Chronic anaemia can slow
growth and result in learning difficulties and behavioural changes
in affected children (Grantham-McGregor 2001; Lozoff 1991).
The symptoms of anaemia vary according to the severity, the age of
the affected person, and whether the anaemia is acute or chronic.
People with anaemia report fatigue, shortness of breath and pal-
pitations. Clinical signs include paleness of the mucosal linings,
such as the tongue, conjunctiva, palm and nail bed (Kalter 1997).
Although palm pallor is commonly used for classification of dis-
ease in children (Meremikwu 2009), diagnosis of anaemia is based
on laboratory tests. The World Health Organization (WHO) has
defined anaemia in pre-school aged children as a haemoglobin
(Hb) concentration of less than 11 g/dL (WHO 2008) and severe
anaemia, often a complication of severe malaria, as a Hb concen-
tration of less than 5 g/dL (WHO 2000). In a study assessing the
short and long term outcome of severe anaemia in Malawian chil-
dren, children hospitalized and treated for severe anaemia had a
significantly higher mortality rate (in-hospital and post-discharge)
than children who were seen in hospital for other conditions and
those from the community (Phiri 2008). Furthermore, researchers
estimate that severe anaemia probably accounts for more than half
of all childhood deaths from malaria in Africa (Crawley 2004).
Children who are affected may need to be admitted to hospital
and may need blood transfusions (Obonyo 2007).
A Cochrane Review has shown that long lasting insecticide-treated
net (LLIN) use was highly effective in reducing childhood mor-
tality and morbidity from malaria and had a positive effect on
anaemia in children (Lengeler 2009). These vector control strate-
gies are a core component of the malaria control programmes
globally and especially in Africa (WHO 2012a). Other measures
to prevent anaemia include prompt and effective treatment of
malaria infections, intestinal helminths and human immunodefi-
ciency virus (HIV), increased use of measures to prevent mother-
to-child transmission of HIV and provision of micronutrient sup-
plementation (Balarajan 2011; Crawley 2004).
Description of the intervention
Intermittent preventive treatment (IPT) is the administration of
a full course of antimalarial treatment to a population at risk of
malaria during a specific time period, regardless of whether or not
they are known to be infected (Greenwood 2006). IPT policies
were first implemented in pregnant women (IPTp) living in areas
with a high rate of seasonal malaria transmission. This treatment
consisted of a single dose of sulphadoxine/pyrimethamine (SP)
given two or three times during the pregnancy, and was introduced
as an alternative to chemoprophylaxis with chloroquine (CQ),
due to the increasing CQ resistance and unpopularity of the drug
(Greenwood 2010). The WHO also recommends that IPT in
infants (IPTi) up to the age of 12 months, should be administered
together with the second and third diphtheria-pertussis-tetanus
(DPT) and measles vaccination of infants in areas that have a
moderate to high transmission rate ofmalaria (WHO2010;WHO
2012a).
IPT was first made available for children (IPTc) after it had been
shown that most children in highly seasonal malaria areas suffer
from malaria and its related complications during the rainy sea-
son (Dicko 2011). Two recent systematic reviews have demon-
strated that IPTc reduces episodes of clinical malaria in areas with
a high rate of seasonal malaria transmission (Meremikwu 2012;
Wilson 2011). Currently, theWHO recommends seasonal malar-
ial chemoprevention (SMC) or IPTc, in seasonal malarial areas
during the transmission season (WHO 2012b). This consists of a
complete treatment course of SP and amodiaquine (AQ), given to
children aged between three to 59 months, at monthly intervals,
during the high risk period of malaria transmission. Children may
receive up to four doses of this antimalarial treatment during the
malaria transmission season with the aim of maintaining thera-
peutic drug levels during the period of high transmission. This
strategy excludes areas with SP resistance outbreak (WHO 2013).
How the intervention might work
Children with severe anaemia, for whom routine management
like blood transfusions and hematinics is insufficient to improve
the Hb level, might benefit from IPT, since it has been shown to
augment the effect of hematinics on Hb recovery when admin-
istered together in anaemic children (Akech 2008; Phiri 2011;
Verhoef 2002). In addition, IPT enables hematological recovery
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by preventing and treating new malaria infections (White 2004).
Combining the effect of IPT, LLIN, and other programs like de-
worming and iron supplementation might add significant ben-
efit in reducing the burden of anaemia in pre-school aged chil-
dren. Iron supplementation is often recommended for children
with anaemia, although there are concerns about an association
between iron supplementation and increased malaria morbidity
and mortality (WHO 2006). However, a recent Cochrane Review
concluded that there is high quality evidence that iron supple-
mentation, even when given together with antimalarial treatment,
does not increase the risk of clinical malariamorbidity ormortality
(Okebe 2011).
ACochrane Review reported that IPT, when given to treatmalaria,
also increased Hb levels of children (Meremikwu 2012). They also
concluded that there is moderate quality evidence that children
given IPT were less likely to have moderately severe anaemia at
follow-up (Hb < 8 g/dL) compared to placebo (Risk ratio (RR)
0.71, 95% confidence interval (CI) 0.52 to 0.98).
Why it is important to do this review
The prevalence of anaemia in pre-school aged children remains
high, especially in children living in Africa and South-East Asia.
The Cochrane Review of IPT in areas with seasonal transmission
of malaria showed promising effects on preventing and treating
anaemia in children (Meremikwu 2012). Although the review in-
cluded all pre-school aged children living in malaria-endemic re-
gions, it did not examine the effects of IPT on children diagnosed
with anaemia.
Since the two systematic reviews on IPT for malaria (Meremikwu
2012; Wilson 2011) have conflicting results on the effect of IPT
on anaemia, a formal assessment of existing studies in a systematic
review can provide physicians, policy makers and researchers with
reliable evidence on the use of IPT in anaemic children living in
malaria-endemic areas with a high seasonal transmission rate.
O B J E C T I V E S
To assess the effect of intermittent preventive antimalarial treat-
ment for children with anaemia living in malaria-endemic areas.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) and cluster-RCTs.
Types of participants
Children with anaemia (Hb < 11 g/dL; WHO 2008) living in
malaria-endemic areas.
Types of interventions
Intervention
IPT for malaria
Control
No IPT for malaria
Co-interventions, such as hematinics or LLINs, should be identi-
cal in both intervention and control groups.
Types of outcome measures
Primary outcomes
• All-cause mortality and hospital admission
Secondary outcomes
• Anaemia at follow-up (Hb < 11g/dL)
• Mean change in Hb (g/dL) from baseline to follow-up
• Mean Hb at follow-up (g/dL)
Search methods for identification of studies
We attempted to identify all relevant studies regardless of the lan-
guage and publication status (published, unpublished, in press and
ongoing).
Electronic searches
We searched the following databases up to 4December 2014 using
the search terms and strategy described in Appendix 1: Cochrane
Infectious Diseases Group Specialized Register, Cochrane Central
of Controlled Trials (CENTRAL), published in The Cochrane Li-
brary (2014, Issue 11); MEDLINE; EMBASE; and LILACS. We
also searched theWHO International Clinical Trial Registry Plat-
form and metaRegister of Controlled Trials (mRCT) for ongoing
trials using “anaemia”, “children”, “intermittent preventive treat-
ment” and “malaria” as search terms.
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Searching other resources
Reference lists
We checked the reference lists of all included studies for relevant
trials.
Data collection and analysis
Selection of studies
Two review authors (MA and AR) independently screened the re-
sults of the literature search for potentially eligible trials. We re-
trieved the full text articles of relevant studies and independently
assessed eligibility using an eligibility form.We contacted trial au-
thors in cases of missing or unclear information. We resolved dis-
crepancies through discussion or alternatively through consulting
the third review author, AMK. We ensured that multiple publica-
tions of the same trial were only included once. We listed excluded
studies, together with the reasons for exclusion, in table format.
Data extraction and management
Two review authors (MA and AR) extracted data independently
using pre-piloted, electronic data extraction forms. We resolved
any disagreements through discussion. We contacted the trial au-
thors in case of missing data.
For each included trial, we extracted data on the trial design, par-
ticipants, intervention, control intervention, outcomes (included
outcomes, measurement of outcomes) and results. For RCTs, we
extracted the number of participants randomized to each treat-
ment arm and the number of participants monitored for each out-
come of interest. For dichotomous data, we extracted the number
of events in each of the treatment arms. For continuous data, we
extracted the arithmetic mean, standard deviations (SDs) and the
number of participants in each group. We reported the measure of
effect for each outcome, RRs or mean differences, with 95% CIs.
Assessment of risk of bias in included studies
Two review authors (MA and AR) independently assessed risk of
bias for each included trial by using the Cochrane Collaboration’s
’Risk of bias’ assessment tool (Higgins 2011). All discrepancies
were resolved through discussion or consultation with AMK.
We classified risk of bias judgements as either low, high or unclear
risk of bias. We assessed the following components for risk of bias
in each included trial as follows:
Sequence generation
We regarded a trial as having: low risk of bias if the sequence gen-
eration was truly random (for example, computer-generated table
of random numbers, tossing a coin); high risk of bias if sequence
generation contained a non-random component (for example, al-
ternate randomization, randomization by birth date); or unclear
risk of bias if the trial authors did not clearly describe the random-
ization process.
Allocation concealment
We regarded trials as having: low risk of selection bias if allocation
was truly concealed (for example, central allocationof participants,
use of sequentially numbered, opaque, sealed envelopes); high risk
of bias if the allocation process was not concealed (for example,
open randomization, unsealed or non-opaque envelopes); or un-
clear risk of bias if the trial authors did not describe the process of
allocation concealment in sufficient detail.
Blinding of participants and personnel
We determined whether blinding was present, who was blinded
and themethods used to blind trial participants and personnel.We
regarded a trial as having: low risk of bias if blindingwas present, or
if the absence of blinding was unlikely to affect the outcomes; high
risk of bias if blinding was absent and likely to affect the results;
or at unclear risk of bias if blinding was not clearly described.
Blinding of outcome assessors
We described whether blinding of outcome assessors was present
and how they were blinded. We regarded a trial as having: low
risk of detection bias if they were blind to knowledge about which
intervention the participants received; high risk of bias if blinding
was absent; and unclear risk if blinding was not clearly described.
Incomplete outcome data
We regarded trials as having: low risk of attrition bias if there was
no missing data or if missing data was balanced across groups and
attrition rates were less that 20%; high risk of bias if there was
missing data (attrition rate higher than 20%) or if missing data was
more prevalent in one of the groups; or unclear risk of bias if trial
authors did not clearly state whether outcome data was missing.
Selective outcome reporting
We regarded a trial as having low risk of reporting bias if it was
evident that all pre-specified outcomes were reported on; high risk
of bias if it was evident that not all pre-specified outcomes were
reported on; or unclear risk of bias if it was unclear whether all
outcomes have been reported on.
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Other bias
We described any important feature of included trials that could
have affected the result.
Measures of treatment effect
We compared dichotomous data using RRs. For continuous data
summarized by arithmetic means and SDs, we presented mean
difference values. We presented all results with their associated
95% CIs.
Unit of analysis issues
We included two trialswith a two-by-two factorial trial design, that
is containing four treatment groups (IPT plus iron; iron only; IPT
only; placebo). We included all four groups in the meta-analyses,
by making use of subgroups (IPT plus iron versus IPT without
iron).
Dealing with missing data
We applied available case analysis to continuous outcomes and
only included data on the known results. The denominator was
the total number of participants who had data recorded for the
specific outcome.
For dichotomous outcomes, we performed analyses on an inten-
tion-to-treat basis. We included all participants randomized to
each group in the analyses and analysed participants in the group
to which they were randomized.
We calculated missing SDs from 95% CIs, if available. Where
95% CIs were not reported with the mean Hb level at follow-up,
we borrowed the SDs reported for the mean Hb levels at baseline
(Higgins 2011). Where mean values were not reported for the
outcome (mean change in Hb from baseline to follow-up) we
calculated means by subtracting the mean value at baseline from
the mean value at follow-up. We imputed the corresponding SD
by calculating a correlation coefficient from a reported mean and
SD (mean change in Hb from baseline to follow-up) in Rohner
2010, after consultation with a statistician. This study examined
the effect of IPT onmalaria and anaemia in children, but included
both anaemic and non-anaemic children and thus we excluded it
from this review.
Assessment of heterogeneity
We inspected forest plots for overlapping CIs and assessed statis-
tical heterogeneity in each meta-analysis using the I² and Chi²
statistics. We regarded heterogeneity as moderate if I² statistic val-
ues were between 30% and 60%; substantial if they were between
50% and 90%; and considerable if they were between 75% and
100%. We regarded a P value of 0.10 or less indicative of statisti-
cally significant heterogeneity.
Assessment of reporting biases
Wedid not formally assess reporting biases, since we only included
six trials in the review.
Data synthesis
We used RevMan 2014 for data analysis. If considerable hetero-
geneity was present, we combined data using random-effectsmeta-
analysis and reported an average treatment effect, since this was
considered to be clinically meaningful. We presented results using
forest plots.
Evidence quality
We assessed the quality of evidence using the GRADE approach
(Guyatt 2011). We rated each outcome as either high (we are very
confident that the true effect lies close to that of the estimate of
the effect); moderate (we are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of
the effect); low (our confidence in the effect estimate is limited:
the true effect may be substantially different from the estimate
of the effect); or very low quality of evidence (we have very little
confidence in the effect estimate: the true effect is likely to be
substantially different from the estimate of effect) (Balshem 2011).
RCTs are regarded as high quality evidence but can be downgraded
within the followingfive categories: study limitations, imprecision,
inconsistency, indirectness and publication bias. Studies can also
be upgraded if there is a large effect, a dose-response effect, or if
all plausible residual confounding would reduce a demonstrated
effect or would suggest a spurious effect if no effect was observed
(Balshem 2011). We summarized our findings in a ’Summary of
findings’ table.
Subgroup analysis and investigation of heterogeneity
We performed the following subgroup analyses:
• Additional interventions to treat anaemia (such as
hematinics or folic acid)
• Hospital recruitment versus community recruitment
We performed subgroup analyses for the following outcomes:
• All-cause mortality and hospital admissions at six months
follow-up
• Anaemia at 12 weeks follow-up
• Mean change in Hb from baseline to follow-up (12 weeks)
• Mean Hb at follow-up (12 weeks)
We assessed differences between subgroups using the Chi2 test
with a P value of 0.05 or less indicating statistically significant
differences between subgroups.
We documented the drugs used for IPT in the footnotes for
each forest plot. There was no evidence of heterogeneity by drug
type, which might be anticipated with emerging sulfadoxine-
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pyrimethamine (SP) resistance, so we did not subgroup by drug
type.
Sensitivity analysis
Due to the limited amount of included trials, we did not perform
sensitivity analysis.
R E S U L T S
Description of studies
See Table 1; Characteristics of included studies; Characteristics of
excluded studies.
Results of the search
Our search yielded 88 records.We excluded 74 studies after screen-
ing abstracts and a further eight studies after assessing eligibility of
full texts. We included six RCTs (3847 participants). See Figure
1.
Figure 1. Study flow diagram.
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Included studies
Trial designs
All included trials were individually RCTs. Two trials with a facto-
rial design (Desai 2003 KEN; Verhoef 2002 KEN) had four trial
arms. One trial had three arms (Tomashek 2001 TNZ) and the
remaining three trials had two trial arms. Most of the included
RCTs had an intervention period of approximately 12 weeks, at
which time outcomes were assessed, and some trials had an ex-
tended follow-up period of up to one year post enrolment.
Location
All included trials were conducted inmalaria-endemic areas. Three
trials were conducted in low endemicity areas: two in The Gambia
(Bojang 2010 GMB; Cox 2013 GMB) and one in eastern Kenya
(Verhoef 2002 KEN). Three trials were conducted in high en-
demicity areas: one in western Kenya (Desai 2003 KEN), one in
southern Malawi (Phiri 2012 MWI) and one in western Tanzania
(Tomashek 2001 TNZ).
Participants
The age of the anaemic children ranged between two months and
nine years. In five trials, children had mild to moderate anaemia
(Hb 5 to 11 g/dL) at enrolment. The remaining trial enrolled
children with Hb levels less than 7 g/dL (Bojang 2010 GMB).
In one trial, children had severe malaria (Phiri 2012 MWI), two
trials included children with uncomplicated malaria (Cox 2013
GMB; Desai 2003 KEN), for two trials malaria was not part of
the inclusion criteria (Bojang 2010 GMB; Tomashek 2001 TNZ)
and one trial excluded children with clinical malaria (Verhoef
2002 KEN). Three trials (Bojang 2010 GMB; Phiri 2012 MWI;
Tomashek 2001 TNZ) recruited children that attended outpatient
clinics or were admitted to hospital, while three trials recruited
children from the community (Cox 2013GMB;Desai 2003KEN;
Verhoef 2002 KEN).
Interventions
Baseline treatments
In four trials, children in intervention and placebo groups received
baseline treatment for malaria or anaemia. In two of these trials,
all children were given a single dose of SP (Desai 2003 KEN;
Tomashek 2001 TNZ). In one trial (Cox 2013 GMB) children
received eitherCQandSPor artemether-lumefantrine (AL) before
randomization to intervention and placebo groups. Phiri 2012
MWI treated all children with intravenous quinine and blood
transfusion while in hospital and AL at discharge. In addition,
Tomashek 2001 TNZ administered a single dose of mebendazole
to all children over the age of 12 months.
In Bojang 2010 GMB only children with malaria were treated
with quinine and SP or CQ and SP. Verhoef 2002 KEN was the
only trial where no baseline treatment was given to children.
Trial interventions
All included RCTs compared IPT to placebo. The types of IPT
used were the following:
• SP (500 mg sulfadoxine/25 mg pyrimethamine per tablet,
given at an approximate dose of 25 mg sulfadoxine/1.25 mg
pyrimethamine per kg) given monthly for an average of 12 weeks
or until the end of the malaria transmission period (Bojang 2010
GMB; Desai 2003 KEN; Tomashek 2001 TNZ; Verhoef 2002
KEN). A drug sensitivity study of SP in a multicentre trial in
Eastern Kenya and Kigoma Tanzania (Gorissen 2000) between
1998 and 2000 showed efficacy of more than 85%. However,
these findings differed from other studies done in East Africa,
which reported on resistance of Plasmodium falciparum to SP
between 1995 and 1997. This finding did not have a strong
association with the clinical evidence (Jelinek 1997; Terlouw
2003). In contrast to East Africa, reports on declining SP efficacy
and its resistance on P. falciparum were already reported by
several studies in The Gambia by 1998 (Dunyo 2006; von
Seidlein 2000).
• AL tablets (20 mg artemether, 120 mg lumefantrine per
tablet, children weighing 15 kg or more received two tablets, less
than 15 kg received one tablet) given as a three day course (six
doses) monthly for 12 weeks (Phiri 2012 MWI). Artemisinin
combination therapies (ACTs) were adopted in most African
countries after 2005. In Malawi, an earlier study (2004 to 2006)
had already shown efficacy of above 85% (Bell 2009). This
finding was supported by another study in the same country
which found less genetic amplification of P. falciparum to
Coartem (Haildar 2009).
• CQ syrup (5 mg/kg) given as a weekly dose (three day
course) for 12 weeks (Cox 2013 GMB). CQ sensitivity studies
conducted in the early 2000s in The Gambia and Mali revealed
low efficacy of CQ (Tekete 2009) with evidence of increased
resistance of CQ to P. falciparum (Ord 2007).
Four trials gave iron as part of the intervention. In two trials,
all children received iron, regardless of whether they were in the
intervention or placebo group (Bojang 2010 GMB; Tomashek
2001 TNZ). Bojang 2010 GMB administered iron for 28 days
and Tomashek 2001 TNZ gave iron and folic acid for 12 weeks.
In the two-by-two factorial trials (Desai 2003 KEN; Verhoef 2002
KEN), children were randomized to receive either iron or placebo.
In addition, children in one of the three intervention groups in
Tomashek 2001 TNZ received vitaminA andC (VAC) three times
a week.
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Co-interventions
Two trials did not report the use of LLINs (Tomashek 2001
TNZ;Verhoef 2002KEN). InCox2013GMB,LLINdistribution
was part of the standard malaria prevention programme and in
Desai 2003 KEN all households were issued with LLINs, but both
studies did not assess the use of LLINs. Bojang 2010GMB assessed
LLIN use at the end of the transmission period (20.7% in IPT
group; 15.3% in placebo) and the reported bed net use in Phiri
2012 MWI was similar in both groups, overall use was 51% (35%
treated net, 16% untreated net).
Outcomes
Trials reported on a variety of outcomes (Table 2).
Haematological outcomes
Four trials reported on the mean Hb concentration at 12 weeks
follow-up or at the end of the transmission period. Only one trial
(Cox 2013 GMB) reported on the mean change in Hb concen-
tration from baseline to follow-up.
Four trials reported on the number of children with anaemia at 12
weeks or at the end of the transmission period. Anaemia was de-
fined as Hb < 11 g/dL in three trials (Desai 2003 KEN; Tomashek
2001 TNZ; Verhoef 2002 KEN). Bojang 2010 GMB reported the
number of children with an Hb < 7 g/dL and Desai 2003 KEN
reported the outcome separately for children with an Hb < 11 g/
dL and those with Hb < 7 g/dL.
Other reported outcomes included mean corpuscular volume
(MCV) at 12 week follow-up (Desai 2003 KEN), serum trans-
ferrin receptor (TfR) concentration at 12 weeks follow-up (Desai
2003 KEN; Tomashek 2001 TNZ), iron deficiency measured as
serum ferritin < 12 µg/L in Verhoef 2002 KEN and as TfR < 8.5
µg/mL in Tomashek 2001 TNZ and change in erythropoietic re-
sponse (Cox 2013 GMB).
All-cause mortality and hospital admissions
All-cause mortality plus hospital readmissions due to severe
anaemia (Hb < 5 g/dL or clinical indication for blood transfusion)
or severe malaria (re-admittance due to confirmed malaria treated
with parenteral quinine) at three and six months was the primary
outcome in Phiri 2012 MWI. All-cause mortality and hospital
readmission because of all-cause severe anaemia or severe malaria
were also reported on separately.
Malaria outcomes
Three trials reported clinical malaria. One trial (Bojang 2010
GMB) did not define clinical malaria. Desai 2003 KEN defined
clinical malaria as an axillary temperature of 37.5°C or higher with
co-existing malaria parasitaemia. Verhoef 2002 KEN reported the
proportion of children with at least one malaria attack, defined as
a temperature of 37.5°C or higher and a positive dipstick result.
Two trials reported malaria parasitaemia (Bojang 2010 GMB;
Desai 2003 KEN). Desai 2003 KEN also reported parasite den-
sities. Cox 2013 GMB reported on the prevalence of submicro-
scopic parasitaemia (detection of parasites’ DNA).
Phiri 2012 MWI reported on clinic visits due to microscopically
confirmed non-severe malaria and Verhoef 2002 KEN on the time
to first occurrence of malaria attack.
Other outcomes
Three trials reported visits to healthcare facilities (outpatients,
clinics, pharmacies) (Bojang 2010 GMB; Desai 2003 KEN; Phiri
2012 MWI). Other outcomes reported across trials included nu-
tritional status at the end of the transmission period, compliance
with treatment regime (Bojang 2010 GMB), adverse drug reac-
tions (Verhoef 2002 KEN) and change in urinary neopterin (Cox
2013 GMB).
Excluded studies
We excluded eight trials (see Characteristics of excluded studies).
Five of these did not include only anaemic children, one did not
have a control group, another trial was a sub-analysis of an included
trial and the intervention of one study was chemoprophylaxis and
not IPT.
Risk of bias in included studies
Overall, risk of bias in included trials was low (see Figure 2 and
Figure 3).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Allocation
All trials used adequate methods to generate a random sequence.
Three RCTs (Bojang 2010 GMB; Cox 2013 GMB; Phiri 2012
MWI) had adequate allocation concealment. The remaining three
trials had insufficient information to make a judgement about risk
of bias and were thus judged as having unclear risk of bias.
Blinding
Five RCTs were at low risk of performance bias and ade-
quately blinded participants and personnel. We judged one trial
(Tomashek 2001 TNZ) to have high risk of bias, since one of the
groups did not receive IPT placebo and the personnel had access
to lists of group assignment.
All included trials were at low risk of detection bias and adequately
blinded outcome assessors.
Incomplete outcome data
Two trials had high risk of attrition bias. Bojang 2010 GMB had a
high rate of loss to follow-up at the end of the transmission period,
23% (136/600) in the intervention group and 21.5% (127/600)
in the placebo group. Although the overall loss to follow-up rate in
Desai 2003 KEN was not high, there was a significant difference
in loss to follow-up at 12 weeks between the placebo group and the
other intervention groups: 4% (6/135) in the IPT + iron group;
8.6% (12/139) in the iron group; 6.6% (9/136) in the IPT group,
and 20.5% (28/136) in the double placebo group. Follow-up data
at 24 weeks follow-up was missing.
For Tomashek 2001 TNZ there was also a difference in children
lost to follow-up. In the placebo group, the loss to follow-up was
6% (5/82), in the IPT group it was 10% (8/81) and in the IPT
+ VAC group it was 13% (10/75). Reasons for missing children
were not stratified according to groups and we judged the risk of
bias to be unclear.
The other three trials had low risk of attrition bias.
Selective reporting
Verhoef 2002 KENdid not report on the primary outcome (mean
Hb concentration at follow-up) and was therefore at high risk of
reporting bias. One trial (Desai 2003 KEN) did not pre-specify
their outcomes in the methods section and we therefore judged
risk of bias to be unclear. The remaining three RCTs had low risk
of reporting bias.
Other potential sources of bias
We did not identify any other sources of bias in the six included
trials.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table 1
All-cause mortality and hospital admissions at six
months
We included three trials (Bojang 2010 GMB; Desai 2003 KEN;
Phiri 2012 MWI) with a total of 3160 children in the fixed-ef-
fects meta-analysis (Analysis 1.1). Results for all-cause mortality
and hospital admissions were included for two trials (Bojang 2010
GMB; Phiri 2012 MWI). Bojang 2010 GMB assessed outcomes
at the end of the malaria transmission period and at the end of the
following dry season. We included results from the dry season fol-
low-up for this outcome. For Desai 2003 KEN, we only included
mortality data since the hospital admissions were not reported.
We extracted mortality data from the study flow-chart.
IPT did not reduce the risk of death or hospital admission com-
pared to placebo (three trials, 3160 participants; Analysis 1.1; I²
= 22%). Subgroup analysis did not show a significant difference
between children receiving iron and children receiving no iron
(Chi² = 0.09, P = 0.76, I² = 0%). There was heterogeneity in the
subgroup that received iron (Chi² = 2.53, P = 0.11, I² = 61%), but
this subgroup included only two trials and random-effects meta-
analysis did not change the overall effect (RR 0.89, 95% CI 0.61
to 1.31).
There was no significant difference between subgroups for areas
with high endemicity versus areas with low endemicity (Chi² =
0.23, P = 0.63, I² = 0%; Analysis 2.1).
Subgroup analysis further stratifying subgroups according to re-
cruitment (hospital admission versus selected from community)
did not show a difference between groups and we thus combined
hospital admissions and community recruitments in the main
analyses.
Children with anaemia at 12 weeks
We included four RCTs (Bojang 2010 GMB; Desai 2003 KEN;
Tomashek 2001 TNZ; Verhoef 2002 KEN) with a total of 2237
children in the fixed-effects meta-analysis (Analysis 1.2). Bojang
2010 GMB assessed outcomes at the end of the malaria transmis-
sion period, therefore length of follow-up depended on time of
enrolment.
Overall, IPT did not have an effect on the risk of anaemia com-
pared to placebo (four trials, 2237 participants, Analysis 1.2; I² =
29%).
Overall the heterogeneity was not remarkable in themeta-analysis,
but there was some suggestion that the subgroup with iron and the
subgroup without iron were slightly different (test for subgroup
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difference: (Chi² = 4.74, P = 0.03, I² = 78.9%). However, the
point estimate and CIs between those receiving iron and those not
receiving iron was similar, and the subgroup analysis was under-
powered to be confident of any conclusion (Analysis 1.2).
There was no significant difference between subgroups for areas
with high endemicity versus areas with low endemicity (Chi² =
1.43, P = 0.23, Analysis 2.2; I² = 30.2%).
Subgroup analysis further stratifying subgroups according to re-
cruitment (hospital admission versus selected from community)
did not show a difference between groups and we thus combined
hospital admissions and community recruitments in the main
analyses.
We did not include one intervention armof Tomashek 2001TNZ,
where children received SP plus VAC, in the meta-analysis. The
risk for anaemia was not significantly different in these children
compared to those that only received SP and vitamin placebo (one
trial, 138 participants, Analysis 3.1).
Mean change in Hb (baseline to 12 weeks)
We included four trials (Bojang 2010 GMB; Cox 2013 GMB;
Desai 2003 KEN; Tomashek 2001 TNZ) with a total of 1672
children in the fixed effects-meta-analysis (Analysis 1.3). Only one
trial (Cox 2013GMB) reported on this outcome andwe calculated
the values for the other four trials. Bojang 2010 GMB assessed
outcomes at the end of the malaria transmission period, therefore
length of follow-up depended on time of enrolment.
Overall, the mean change in Hb concentration from baseline to
follow-up was 0.32 g/dL higher in the IPT group compared to
the placebo group (Mean difference (MD) 0.32, 95% CI 0.19 to
0.45; four trials, 1672 participants; Analysis 1.3; I² = 18%)
Subgroup analysis did not show a difference between children
receiving iron and children receiving no iron (Chi² = 0.25, P =
0.62, I² = 0%).
There was also no significant difference between subgroups for
areas with high endemicity versus areas with low endemicity (Chi²
= 0.17, P = 0.68, I² = 0%; Analysis 2.3).
Subgroup analysis further stratifying subgroups according to re-
cruitment (hospital admission versus selected from community)
did not show a difference between groups and we thus combined
hospital admissions and community recruitments in the main
analyses.
We did not include one intervention armof Tomashek 2001TNZ,
where children received SP plus VAC, in the meta-analysis. The
mean change in Hb from baseline to follow-up in these children
was not different from the mean change in Hb in children that
only received SP (MD 0.00, 95%CI -0.48 to 0.48; one trial, 138
participants, Analysis 3.2).
Mean Hb at 12 weeks
We included four trials (Bojang 2010 GMB; Cox 2013 GMB;
Desai 2003 KEN;Tomashek 2001 TNZ)with a total of 1672 chil-
dren in the random-effects meta-analysis (Analysis 1.4). Bojang
2010 GMB assessed outcomes at the end of the malaria transmis-
sion period, therefore length of follow-up depended on time of
enrolment. Cox 2013 GMB did not report on this outcome, but
we calculated the value using the reported baseline and the change
from baseline values.
Overall, the mean Hb at 12 weeks follow-up was on average 0.35
g/dL higher in the IPT group compared to the placebo group
(MD 0.35, 95% CI 0.06 to 0.64; four trials, 1672 participants,
Analysis 1.4; T² = 0.08; I² = 76%). One trial (Desai 2003 KEN)
caused heterogeneity. If we remove this trial from the analysis,
heterogeneity is reduced to 0%.
Subgroup analysis did not show a difference between children
receiving iron and children receiving no iron (Chi² = 0.89, P =
0.35, I² = 0%).
There was also no significant difference between subgroups for
areas with high endemicity versus areas with low endemicity (Chi²
= 0.85, P = 0.36, I² = 0%; Analysis 2.4).
Subgroup analysis further stratifying subgroups according to re-
cruitment (hospital admission versus selected from community)
did not show a difference between groups and we thus combined
hospital admissions and community recruitments in the main
analyses.
We did not include one intervention armof Tomashek 2001TNZ,
where children received SP plus VAC, in the meta-analysis. The
mean Hb in these children was not different from the mean Hb in
children that only received SP (one trial, 138 participants, Analysis
3.3).
D I S C U S S I O N
Summary of main results
The included trials did not demonstrate a difference in mortality
or hospital admissions at six months when administering IPT,
compared to not administering IPT to anaemic children living
in malaria-endemic areas (moderate quality evidence); and also did
not demonstrate a difference in the prevalence of anaemia at 12
weeks amongst children that received IPT compared to those that
did not receive IPT (moderate quality evidence). IPT for anaemic
children living in malaria-endemic areas probably increases the
mean change in Hb levels from baseline to follow-up at 12 weeks
(moderate quality evidence); andmay improveHb levels at 12weeks
(low quality evidence).
Overall completeness and applicability of
evidence
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All six included trials were conducted in malaria-endemic areas,
four trials in seasonal and two in perennial malaria transmission ar-
eas. Three of the six trials were conducted in areas of low endemic-
ity. Anaemic children were recruited either in hospital, where they
were treated for severe anaemia, or in the community through a
screening procedure. Hb levels considered eligible for inclusion
in a study differed across trials. While some trials only recruited
children with severe anaemia (Hb 5.0 to 8.0 g/dL; or Hb < 7 g/
dL), others only included children with mild anaemia (Hb 7.0
to 10.9 g/dL). In all but two trials, children received treatment
for either anaemia or malaria before randomization, which might
explain why the subsequent effect of IPT was not very big. We
found a small, statistically significant effect on mean Hb levels at
follow-up, and on mean change in Hb from baseline to follow-up.
However, an increase in Hb levels of 0.32 g/dL at twelve weeks
is too small to add a clinically significant effect on children with
moderate or severe anaemia.
In the past decade, a decrease in malaria endemicity has been
recorded in most of sub-Saharan Africa. There has been a signifi-
cant decline in malaria prevalence which coincides with a decline
in the transmission potentials measured through the recent P. fal-
ciparum infectious inoculations rates downturn by the Anopheles
mosquito (Killeen 2007). These in turn have resulted in a further
downturn in new malaria infections that may have contributed
to the recent shift in anaemia morbidity decline in settings with
malaria transmission (Kabanywanyi 2012). Malaria mortality and
cumulative probability of deaths have thus also continued to de-
cline steadily (Rumisha 2014). A combination of manymalaria in-
terventions have resulted in these reductions, including improved
access to effective antimalarial combination therapy, vector con-
trol using LLINs and indoor residual spraying as well as intermit-
tent presumptive treatments in infants and pregnant women (Alba
2014).
The results of this Cochrane Review thus need to be interpreted
in light of these changes in malaria endemicity. Of the included
trials, only three were published in the last five years (Bojang
2010 GMB; Cox 2013 GMB; Phiri 2012 MWI), with two of
these trials having been conducted in The Gambia, where malaria
endemicity is regarded as being low. The remaining trials were all
published over ten years ago; one of these in an area of highmalaria
endemicity (Desai 2003 KEN) and one where, at the time of the
trial, malaria endemicity was moderate to high (Tomashek 2001
TNZ). There could be larger effects of IPT in areas where malaria
endemicity is higher.
In addition, the mild effect of IPT in improving Hb levels may
be associated with the fact that there are other causes for severe
anaemia apart from malaria. Calis 2008 found additional associa-
tions between severe anaemia and bacteraemia, hookworm, HIV
infection, and Vitamin A and B12 deficiency. They also found an
inverse association between iron deficiency and severe anaemia.
Quality of the evidence
We assessed the quality of the body of evidence by using the
GRADE approach (Guyatt 2011). We made judgements on the
quality of evidence for each outcome by looking at trial limita-
tions, inconsistency, imprecision, indirectness and the likelihood
of publication bias (Balshem 2011). Our results show that there
is moderate quality evidence that IPT did not have an effect on
death or hospital admissions at six months; and anaemia at 12
weeks; and that the mean change in Hb from baseline to 12 weeks
was slightly higher amongst children receiving IPT. This means
that, when looking at these three outcomes, further research is
likely to have an important impact on our confidence in the esti-
mate of effect and may change the estimate. We found low quality
evidence that the mean Hb level at follow-up was slightly higher
amongst children receiving IPT, meaning that further research is
very likely to have an important impact on our confidence in the
estimate of the effect and is likely to change the estimate. We have
presented the reasons for downgrading the quality of evidence in
the footnotes of Summary of findings for the main comparison.
Potential biases in the review process
Weattempted tominimise bias in the reviewprocess by conducting
a comprehensive search of published and unpublished literature,
without language restrictions. Two review authors independently
screened abstracts, extracted data and assessed risk of bias. We
resolved any discrepancies by involving a third party. We were
unable to create funnel plots to assess reporting biases, since less
than 10 RCTs met the inclusion criteria.
Agreements and disagreements with other
studies or reviews
We are not aware of another review on the treatment of anaemic
children with IPT, but two recent reviews on IPT for malaria
(Meremikwu 2012; Wilson 2011) included anaemia as one of the
outcomes. Although the included children in these reviews did
not necessarily have anaemia at enrolment, our findings on the
prevalence of anaemia resonate with those of Wilson 2011 (RR
0.84, 95% CI 0.59 to 1.21), but are contradictory to those of
Meremikwu2012.Meremikwu 2012 found a reduced risk ofmod-
erate anaemia (RR 0.71, 95% CI 0.52 to 0.98; 8805 participants,
five trials) as well as a reduced risk of severe anaemia (RR 0.24,
95% CI 0.06 to 0.94; 5964 participants, two trials) in children
with malaria receiving IPT compared to those not receiving IPT.
The markedly reduced risk of anaemia in Meremikwu 2012 could
be due to subgroup analysis (severe andmoderate anaemia groups)
which was not done inWilson 2011. Neither of the reviews found
a significant difference in Hb levels at the end of follow-up in
children receiving IPT compared to children not receiving IPT
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(Meremikwu 2012; Wilson 2011). We found a small, statistically
significant effect of IPT on Hb levels.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The trials did not demonstrate a difference in all-cause mortality
and hospital admissions at six months; and prevalence of anaemia
at 12 weeks amongst children that received IPT compared to those
that did not receive IPT. IPT probably increases the Hb levels of
anaemic children. Despite the small benefits of IPT on Hb levels
of anaemic children, it does not warrant routine administration of
IPT to anaemic children. However, one needs to take into consid-
eration that the majority of trials were conducted in low endemic-
ity areas, where any effect is likely to be modest.
Implications for research
Only one trial was adequately powered to detect a difference in
the risk of all-cause mortality and hospital admissions due to se-
vere anaemia or severe malaria. Future trials should be adequately
powered to detect differences in patient-orientated outcomes (for
example, all-cause mortality) and consideration should be given
to malaria endemicity.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bojang 2010 GMB
Methods Trial design: Individually randomized, controlled double-blind trial
Multicentre trial: Yes
Trial duration: 2 years
Participants Recruitment:Children presenting to the out-patient clinic or ward at the Royal Teaching
Hospital, Banjul; Medical Research Council Hospital, Fajara; and major health centres
at Birkama, Essau and Faji Kunda during 2003 and 2004 transmission period (July to
December), Sibanor was added during the 2004 period
Inclusion criteria:
• Age: 3 months to 9 years
• Anaemia: Hb < 7 g/dL
• Sickle-cell anaemia: not reported
• Other: signed consent from guardian
Other co-morbidities: Not reported
Sample size: 1200 enrolled
Interventions Total number of intervention groups: 2
Presumptive treatment for all participants:
• Malaria was treated with intramuscular quinine followed by SP (majority) or CQ
plus SP
• Children stayed in hospital until all signs of respiratory distress had subsided and
Hb concentration had increased over that found on admission
• Children with Hb < 5 g/dL received blood transfusion
• All children received iron (ferrous fumerate syrup: 2 mg/kg) for 28 days, starting
at time of discharge
• 1st follow-up 7 days after discharge: Hb measurement and blood films for
malaria, and treatment of any medical condition
Interventions:
1. IPT with SP
2. Placebo (lactose and maize starch)
Dose and timing of intervention:
• SP dose: 1.25 mg pyrimethamine/25 mg sulphadoxine per kg
• 1st dose (SP or placebo): at 7 day follow-up
• Monthly doses until end of transmission season
Duration of intervention period: until the end of the transmission season (July to
December)
Place and person delivering intervention:
• 1st dose administered by project staff at the hospital or health centre where the
child had been admitted
• Monthly doses were given at health centre closest to where the child was living by
trained field workers under supervision of clinic staff
Co-interventions:
• ITN use: was assessed at the end of the transmission period (20.7% in IPT group;
15.3% in placebo group)
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Bojang 2010 GMB (Continued)
• Other: none
Additional treatments:
• Children with fever ≥ 37.5°C or a history of recent fever and malaria
parasitaemia were treated with SP and CQ
• Children with severe malaria were treated with IM quinine
• Children that presented with uncomplicated malaria within one week of receiving
SP chemoprevention received oral quinine
• Children with Hb < 9 g/dL were treated with iron for a further 28 days if they
had completed their initial iron treatment
• Children with severe anaemia were referred for admission
Co-interventions equal in each arm? (if not, describe): Yes
Outcomes Primary outcome:
1. Proportion of children with moderate or severe anaemia at the end of the
transmission period
Secondary outcomes:
1. Mean Hb level at end of transmission period
2. Clinical episodes of malaria during the surveillance period
3. Outpatient attendance
4. Prevalence of parasitaemia and splenomegaly
5. Nutritional status at the end oft he transmission period
6. Compliance with treatment regimen
Measurement time points:
• Day 7: Hb, blood film
• Passive surveillance during intervention period
• End of malaria season
• End of dry season
How were outcomes assessed?
• Hb and blood film at day 7 and end of malaria transmission season
• Passive morbidity surveillance during intervention period
Interviews with mothers at end of dry season
Notes Country: The Gambia
Setting: Urban and peri-urban
Transmission area: Seasonal transmission
Source of funding: Gates Malaria partnership
Conflict of interest stated: Authors state that they have no competing interests
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “children were individually randomised
into either the SP or the placebo group in
a 1:1 ratio at the time of admission, using
permuted blocks of 12 generated by com-
puter using the STATA program. Block-
swere not split across centres”
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Bojang 2010 GMB (Continued)
Allocation concealment (selection bias) Low risk “Tablets (enough for 6 doses) were packed
into envelopes bearing the randomisation
number by MRC staff not involved in the
trial in any other way. The next envelope
in sequence was assigned to the child at the
time of their admission to hospital”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “None of the investigators, health care cen-
tre staff or laboratory staff participating in
the trial had access to the code during the
trial”. Placebo and active tablet were iden-
tical in shape and colour
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “None of the investigators, health care cen-
tre staff or laboratory staff participating in
the trial had access to the code during the
trial”
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up was similar in both
groups (SP: 23%; placebo: 21.5%), but was
over 20% in each group
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported and
checked with protocol
Other bias Low risk Discrepancy between text and flow-chart
regarding number of children seen at fol-
low-up
Cox 2013 GMB
Methods Trial design: Population-based RCT (proof of concept study)
Multicentre trial: No
Trial duration: 2007 to 2008
Participants Recruitment: Eligible children identified through active and passive malaria surveillance
in participating communities (West Kiang district, lower river region, The Gambia)
Inclusion criteria:
• Age: 12 to 72 months
• For enrolment: Uncomplicated malaria at day 0 (history of fever 48 hours prior to
presentation or a measured temperature > 37.5°C with peripheral parasitaemia)
• For randomization: Anaemia Hb 6.9 to 11.0 g/dL on day 3 with no peripheral
parasitaemia
• Sickle-cell anaemia: not reported
Exclusion criteria:
• Unable to take oral medication
• Features of severe malaria
• Known haemoglobinopathy
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Cox 2013 GMB (Continued)
• Enrolled in another project
• Had already received antimalaria drugs from outside the project
• Were prescribed other drugs with potential antimalarial or anti-anaemic effects
(for example, cotrimoxazole or haematinics)
• Severely wasted children
Other co-morbidities: Not reported
Sample size: Enrolled into trial: 132; randomized to receive IPT/placebo: 96
Interventions Baseline treatment for all children:
• CQ syrup (3 days) with SP on day 0 (52 children in 2007)
• AL course (80 children in 2007 and 2008)
Total number of intervention groups: 2
1. IPT (CQ)
2. Placebo
Dose and timing of intervention:
• Weekly CQ or placebo syrup: 50 mg CQ base per 5 mL at a dose of 5 mg/kg for 3
days
Duration of intervention period: 90 days (12 weeks)
Place and person delivering intervention:
• Study nurse administered syrup at home of child
Co-interventions:
• ITN use: ITN distribution part of standard malaria but trial does not report the
use of bed nets per group
• Other: none
Additional treatments:
• Comorbidities were treated accordingly avoiding cotrimoxazole and haematinics
Children with positive tests were treated with either CQ/SP (2007) or ACT (2007 and
2008)
Co-interventions equal in each arm? (if not, describe):
Yes
Outcomes Primary outcome:
1. Hb change from day 3 post-treatment (randomization to IPT or no IPT)
Secondary outcomes:
1. Changes in erythropoietic response
2. Changes in urinary neopterin
3. Prevalence of submicroscopic malaria parasitaemia
4. Hb change in 2 placebo groups to investigate effects of initial malaria treatment
therapy
Measurement time points:
• Baseline (day 3); days 15, 30, 45, 70, 90
How were outcomes assessed?
• Fingerprick or venous blood taken by study nurse at follow-up visits
• Active and passive surveillance
• Twice weekly temperature monitoring of enrolled children by village assistants
• Children with fever screened for malaria with rapid test
Notes Country: The Gambia
Setting: Rural
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Cox 2013 GMB (Continued)
Transmission area: Seasonal transmission
Source of funding: UK Medical Research Council
Conflict of interest stated: Authors stated no competing interests.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The block randomisation to the post-
malaria treatment of weeklyCQ or placebo
in both 2007 and 2008 was double blinded
and was carried out in blocks of eight.
The randomisation codes were generated
by a staff member independent of the study
team and held by the external trial moni-
tor”
Allocation concealment (selection bias) Low risk “Treatment codes were labelled A to H and
placed in sequentially numbered, opaque,
sealed envelopes held by the study nurses.
Allocation to the treatment was by match-
ing the code in the envelope to a bottle
of the intervention labelled with the same
code and then labelledwith the subject ID”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both participants and personnel were
blinded, intervention and placebo syrups
were in similar amber-coloured bottleswith
matching caps and labels
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded trial, treatment codes held
by external trial monitor
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for, loss to fol-
low-up: 2% in IPT group; 7% in placebo
group. All lost due to second malaria
episode
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported on.
Other bias Low risk No other sources of bias identified.
25Intermittent preventive antimalarial treatment for children with anaemia (Review)
Copyright © 2015 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Desai 2003 KEN
Methods Trial design: RCT with 2 X 2 factorial design
Multicentre trial: no
Trial duration: Children were screened between April to November 1999
Participants Recruitment: All resident children in 15 villages in Asembo, Bondo district, Kenya were
screened
Inclusion criteria:
• Age: 2 to 36 months
• Anaemia: mild anaemia (Hb 7.0 to 10.9 g/dL)
• Malaria: aparasitaemic or parasite counts < 20,000 parasites/mm3
• Sickle-cell anaemia: children with HbSS phenotype excluded
• Other: no reported iron supplementation, SP treatment or blood transfusions
within the last 2 weeks
Other co-morbidities: Not reported
Sample size: 554 participants randomized; 546 enrolled; 491 followed up at 12 weeks;
468 followed up at 24 weeks
Interventions Total number of intervention groups: 4
Presumptive treatment for all participants: single dose of SP (500 mg sulphadoxine
and 25 mg pyrimethamine per tablet). Children ≤ 10kg received half a tablet, children
> 10kg received one tablet
1. IPT (SP) + iron
2. IPT (SP) + iron placebo
3. IPT placebo + daily iron
4. IPT placebo + iron placebo (double placebo)
Dose, and timing of intervention: IPT with SP (or placebo) at 4 and 8 weeks; iron
(or placebo) given daily for 12 weeks (3 to 6 mg/kg/day, orally). IPT given as crushed
tablets mixed with water
Duration of intervention period: 12 weeks
Place and person delivering intervention:
• Iron delivered through daily home visits by staff
• Unclear where SP presumptive dose was administered
• Unclear where and by whom other doses of SP were given - not reported
Co-interventions:
• ITN use: All households were issued with ITNs but the use thereof was not
further assessed
• Other: none
Additional treatments: Children with symptomatic malaria (temp ≥ 37.5°C with any
malaria parasitaemia or parasitaemia > 5000 parasites/mm3) received oral quinine (10
mg/kg, 3 times/day for 7 days). Children who developed severe malaria, severe anaemia
(Hb < 5.0g/dL) or other severe disease requiring hospitalization were referred for further
treatment
Co-interventions equal in each arm? (if not, describe):
Yes
Outcomes Outcomes not specified according to primary and secondary outcomes:
1. Hb concentration ( measured in g/dL)
2. Hematological recovery (Hb ≥11 g/dL before or at week 12)
3. Severe anaemia (Hb < 7g/dL before or at week 12)
4. MCV (measured in fL)
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Desai 2003 KEN (Continued)
5. sTfR concentration (measured in µg/mL)
6. Parasite density (parasites/mm3)
7. Malaria parasitaemia
8. Clinical malaria (axillary temperature 37.5°C with co-existing malaria
parasitaemia)
9. Clinic visits (Incidence, number of episodes)
Measurement time points: Every 4 weeks
How were outcomes assessed?
• Home visits every 2 weeks for completion of a morbidity questionnaire and
assessment of cutaneous reactions and axillary temperature
• Fingerprick or heel-prick blood samples were obtained every 4 weeks (just before
the next dose of SP or SP placebo) for Hb levels and presence of malaria parasites
• The frequency of local clinic and hospital attendance was monitored using a
passive surveillance system
Notes Country:Western Kenya
Setting: Rural
Transmission area: Perennial transmission
Source of funding:US agency for International Development, Netherlands Foundation
for the advancement of Tropical research
Conflict of interest stated: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Balanced block randomisation (8 chil-
dren/block) and a random number listing
generated independently before the study”
Allocation concealment (selection bias) Unclear risk Children were assigned to 1 of the 4
groups sequentially according to the ran-
dom number listing by one author. Drugs
and placebos were identical. Code to true
drug and placebo assignment was revealed
only after completion of analysis. Still un-
clear whether allocation was concealed suf-
ficiently - did they use numbered envelopes
or bottles?
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo and trial drugs were identical; par-
ticipants (or their mothers) and staff ad-
ministering the drugs were thus not aware
of the study group. The code was only bro-
ken after data analysis
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo and trial drugs were identical; staff
assessing outcomes were thus not aware of
the trial group. The code was only broken
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Desai 2003 KEN (Continued)
after data analysis
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up at 12 weeks: 4% (IPT
+ iron), 8.6% (iron), 6.6% (IPT) and
20.5% (double placebo). Reported rea-
son: mostly migration (23/28 for double
placebo group), loss to follow-up at 24
weeks - data missing
Selective reporting (reporting bias) Unclear risk Outcomes not listed in Methods section
(protocol?).
Other bias Low risk No.
Phiri 2012 MWI
Methods Trial design: Randomized double-blind, placebo-controlled trial
Multicentre trial: Yes
Trial duration: June 2006 to August 2009
Participants Recruitment: Children were recruited from four hospital in southern Malawi: Queen
Elizabeth Central hospital (Blantyre), Chikwawa District hospital, Thyolo District hos-
pital, Zomba Central hospital
Inclusion criteria:
• Age: 4 to 59 months
• Anaemia: admitted with and treated for severe malarial anaemia
• Convalescent children surviving hospital stay (received transfusion and completed
the course of intravenous quinine) with Hb > 5g/dL
• Weight > 5 kg
• Able to switch to oral medication
• Sitting unaided
Exclusion criteria:
• Sickle-cell anaemia
• Blood loss due to trauma
• Haematological malignancy
• Known bleeding disorder
• Hypersensitivity to AL
• Treatment with AL within a week of admission
• Non-residency in trial area
• Previous participation in the trial
• Participation in another clinical trial
• Known need for medication prohibited during the intervention period
• Surgery scheduled during the trial
Other co-morbidities: 8% of children were infected with HIV
Sample size: 1431 randomized, 1414 allocated to groups; analysed 4310
Interventions Presumptive treatment for all participants: Six doses of AL as part of the standard 3
day course in hospital. Children < 15 kg received one tablet; children > 15 kg received
2 tablets, once every 12 hours for 3 days
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Phiri 2012 MWI (Continued)
Total number of intervention groups: 2
1. AL
2. Placebo
Dose and timing of intervention:
• AL or placebo: Children < 15kg received one tablet; children > 15kg received 2
tablets, once every 12 hours for 3 days at 1 month and 2 months post discharge
Duration of intervention period: 3 months
Place and person delivering intervention:
• The first daily dose (both at 1 and 2 months pd) was given by trial team member
who visited the home every morning for 3 day
• The second dose was left with the parent or guardian to give in the evening
(adherence assessed the following morning)
Co-interventions:
• ITN use: similar in both groups; 35% used treated net; 16% used untreated net;
and 48% used no net (self-reported)
• Other: none
Additional treatments:
• Rescue treatment for acute malaria
• Discharge - month 3: oral quinine for 5 days
• Month 4 to 6 (extended follow-up period): AL
• Treatment for severe malaria
• Discharge - month 3: intravenous quinine and oral quinine for 5 days
• Month 4 to 6 (extended follow-up): intravenous quinine and AL
• Children with severe disease were admitted to hospital
• Children with recurrent severe anaemia received blood transfusions
• Bacterial and other infections treated as per physician’s discretion
Co-interventions equal in each arm? (if not, describe): Yes
Outcomes Primary outcome:
1. Composite outcome of all-cause mortality and hospital readmission because of
all-cause severe anaemia (Hb < 5 g/dL or clinical indication for blood transfusion) or
severe malaria (readmittance to hospital due to confirmed malaria treated with
parenteral quinine) between 1 and 6 months
Secondary outcomes:
1. All-cause mortality
2. Hospital readmission because of all-case severe anaemia or severe malaria
3. All-cause hospital admission
4. All-cause sick child clinic visits
5. Clinic visits because of microscopically confirmed non-severe malaria
Measurement time points:
• Observation time divided into 3 periods:
• Discharge - month 1 pd (before IPT)
• 1 to 3 months pd (IPTpd period)
• 4 to 6 months pd (extended follow-up period)
• All children seen at 6 months for assessment of Hb and malaria parasitaemia
• Passive case detection from discharge to month 6
How were outcomes assessed?
• 6 month follow-up by passive case detection: mothers were asked to bring
children to a study clinic if they had fever or were unwell. Standardized forms used to
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Phiri 2012 MWI (Continued)
record information; Hb, temp and malaria smear
Notes Country:Malawi
Setting: Urban/peri-urban/rural
Transmission area: Perennial
Source of funding: Netherlands African Partnership for Capacity Development and
Clinical Interventions against Poverty-relatedDiseases; UBSOptimus foundation; Gates
Malaria Partnership
Conflict of interest stated: Authors declared no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random num-
bers, “stratified by hospital and weight
group (< 15 kg and 15 kg or more) in ran-
domly varying block sizes of two, four, or
six”
Allocation concealment (selection bias) Low risk Sequentially numbered envelopes contain-
ing AL or placebo.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Authors did not mention that placebo and
ALwere identical tablets, but described the
trial as “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking was maintained and the code only
broken once all data sets were closed
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for. Loss to fol-
low-up rates similar across groups (7% at 6
months)
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported on.
Other bias Low risk No.
Tomashek 2001 TNZ
Methods Trial design: Randomized double-blind trial
Multicentre trial: No
Trial duration: March 1998 to May 1998
Participants Recruitment: Children living in refugee camp diagnosed with clinical anaemia
Inclusion criteria:
• Age: 6 to 59 months
• Anaemia: Hb 5.0 to 8.0 g/dL
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Tomashek 2001 TNZ (Continued)
• Malaria: severe malarial infection excluded
• Informed consent
Exclusion criteria
• Sickle-cell anaemia
• Signs or symptoms of heart failure
• splenomegaly
Other co-morbidities: Hookworm
Sample size: 238 randomized, 215 analysed
Interventions Presumptive treatment for all participants:
• Treatment for malaria with SP (> 48 months: one SP tablet (500 mg sulphadoxine
and 25 mg pyrimethamine); 12 to 47 months: half a tablet; 6 to 12 months: quarter of
a tablet)
• Mebendazole (24 to 59 months one tablet (500 mg mebendazole); 12 to 23
months half a tablet; 6 to 12 months did not receive)
Total number of intervention groups: 3
1. Vitamin placebo 3X per week
2. Vitamin placebo + SP
3. VAC + SP
Dose, and timing of intervention:
• Vitamin (or placebo) given 3 times a week (> 18 months: chewable tablet of 400
µg vitamin A and 75 mg vitamin C; < 18 months: chewable tablet: 400 µg vitamin A
and 30 mg vitamin C)
• SP week 4, 8, and 12 (> 48 months: one SP tablet (500 mg sulphadoxine and 25
mg pyrimethamine); 12 to 47 months: half a tablet; 6 to 12 months: quarter of a tablet)
Duration of intervention period: 3 months
Place and person delivering intervention:
• Home health visitor administrated one dose of iron and placebo or iron and VAC
at weekly home visits
• At visits parents were given 2 additional doses oft he appropriate treatment to be
given on every second day for that week
• In addition, each participant visited the clinic monthly (at week 4, 8, 12) for
physical examination, weight and height measurement, Hb measurement, malaria
blood smear
• Participants in group 2 and 3 were given monthly doses of SP at this visit
Co-interventions:
• ITN use: not reported
• Other: Iron and folic acid supplement for all children (> 18 months: one tablet
containing 250 µg ferrous fumerate (= 60mg of elemental iron) and 250 µg folic acid
three times a week; < 18 months received half a tablet 3 times a week)
Additional treatments:
• Participants in group 1 were given CQ if they presented to the clinic with
symptomatic malaria
Co-interventions equal in each arm? (if not, describe): No
Outcomes Outcomes not specified as primary or secondary outcomes
1. Mean Hb
2. Prevalence of anaemia (Hb < 11.0 g/dL)
3. Mean TfR level
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Tomashek 2001 TNZ (Continued)
4. Prevalence of iron deficiency (TfR < 8.5 µg/mL)
5. Proportion of positive high density parasitaemia
Measurement time points:
• Hb: enrolment, week 4, 8 and 12
• TfR: enrolment, week 12
How were outcomes assessed?
• At each monthly visit: physical examination, height and weight measurement, Hb
and malaria smear
• Laboratory measurements
Notes Country: Tanzania
Setting: Rural
Transmission area: Not reported
Source of funding: Woodruff Foundation, Atlanta, Georgia.
Conflict of interest stated: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomization list.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel distributing medications had ac-
cess to the list of group assignment; group
1 did not receive SP placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The study coordinator and the study
nurse, who were responsible for distribut-
ing medications, were the only team mem-
bers with access to the register containing
participants’ names and group assignment.
All other research team members were
blinded toparticipants’ treatment group as-
signment”. Laboratory workers were not
aware of group assignment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants accounted for. Loss to fol-
low-up rates: Group 1: 6%, Group 2: 10%;
Group 3: 13% reasons for loss to follow-up
not stratified according to groups
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported on.
Other bias Low risk No.
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Verhoef 2002 KEN
Methods Trial design: Double-blind, placebo controlled trial with a 2x2 factorial design
Multicentre trial: No
Trial duration: 1998 to 2000
Participants Recruitment: Children were recruited (randomly selected) from communities neigh-
bouring the research clinic in the Mtito Andei Division, Eastern Province, Kenya at the
start of the rainy season
Inclusion criteria:
• Age: 2 to 36 months
• Anaemia: Hb 6.0 to 11.0 g/dL
• Sickle-cell anaemia: not reported
• Other:
• Temperature < 37.5°C
• No symptoms suggestive of malaria or anaemia
• No systemic illness in combination with a blood dipstick result showing current
or recent malarial infection
• Signed consent from parents
• No allergy to sulfa drugs
• No history of using drugs containing sulfa in previous 3 weeks
• Positive dipstick result without symptoms of systemic illness were included
Other co-morbidities: Not reported
Sample size: 328 randomized, 307 analysed
Interventions Total number of intervention groups: 4
1. IPT (SP) + iron
2. IPT (SP) + iron placebo
3. IPT placebo + iron
4. IPT placebo + iron placebo
Dose, and timing of intervention:
• SP: 1.25 mg pyrimethamine/25 mg sulphadoxine per kg every 4 weeks
• Iron: ferrous fumerate suspension, targeted dose: 6 mg elemental iron/kg/week
administered twice per week
Duration of intervention period: 12 weeks
Place and person delivering intervention:
• Iron (or placebo) administered by community health workers twice a week,
mothers took children to health workers (place unknown)
• SP (or placebo) administered by clinical officer
Co-interventions:
• ITN use: not reported
• Other: none
Additional treatments:
• Children withdrawn and treated appropriately if they had
• Hb < 5.0 g/dL
• Severe and complicated malaria
• Manifestations of other diseases
• Children with malaria attacks were treated with amodiaquine or halofantrine if
unsuccessful
• Treated for other common illnesses
Co-interventions equal in each arm? (if not, describe): Yes
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Outcomes Primary outcome:
1. Hb concentration at the end of follow-up (12 weeks)
2. Proportion of children with at least one malaria attack (defined as presence of
fever, that is temperature ≥ 37.5°C, and a positive dipstick result)
Secondary outcomes:
1. Anaemia (Hb < 11.0 g/dL)
2. Iron deficiency (serum ferritin concentration < 12 µg/L)
3. Adverse drug reactions
4. Time to first occurrence of malaria attack
Measurement time points:
• Baseline, 4 weeks, 8 weeks, 12 weeks
How were outcomes assessed?
• Capillary blood tested for malaria (dipstick) and Hb measured at each visit (4, 8,
12 weeks)
Surveillance and monitoring of illness episodes and adverse effects at twice weekly meet-
ings with community healthworker (questionnaires)
Notes Country: Kenya
Setting: Unclear - rural?
Transmission area: Seasonal transmission
Source of funding: Netherlands foundation for the Advancement of Tropical Research
Conflict of interest stated: Declared no conflicts. Author contacted for follow-up Hb
concentration values
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The allocation schedule was generated by
one of us (HV) for each block, by means of
tables with randomised permutations, and
only after acceptance of all childrenmaking
up a block”
Allocation concealment (selection bias) Unclear risk “The order of the children listed in each
block was concealed from the person gen-
erating the allocation schedule” - unclear,
was this not the same person?
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded, placebos and ac-
tive compounds were indistinguishable in
taste and appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk None of the field investigators was aware
of the code until after crude analysis and a
plan for further analysis had been prepared
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Verhoef 2002 KEN (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for. Loss to fol-
low-up rates similar across groups
Selective reporting (reporting bias) High risk Do not report on mean Hb concentrations
(primary outcome), only on the difference
in Hb concentration between groups
Other bias Low risk No.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bojang 1997 GMB Intervention is chemoprophylaxis, not IPT.
Browne 2005 Anaemia not part of inclusion criteria - study assessed effects on preventing anaemia
Grobusch 2007 Anaemia not part of inclusion criteria.
Kweku 2008 Anaemia not part of inclusion criteria.
Massaga 2003 Anaemia not part of the inclusion criteria.
Nakibuuka 2009 No control group - comparing two malaria treatment regimes.
Rohner 2010 Anaemia not part of the inclusion criteria.
Terlouw 2004 Subanalysis of Desai 2003 KEN.
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D A T A A N D A N A L Y S E S
Comparison 1. IPT versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality plus hospital
admissions at 6 months
3 3160 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.71, 1.13]
1.1 Iron 2 1474 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.56, 1.67]
1.2 No iron 2 1686 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.68, 1.14]
2 Children with anaemia at 12
weeks
4 2237 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.88, 1.07]
2.1 Iron 4 1801 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.74, 1.02]
2.2 No iron 2 436 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.96, 1.23]
3 Mean change in Hb (baseline to
12 weeks)
4 1672 Mean Difference (IV, Fixed, 95% CI) 0.32 [0.19, 0.45]
3.1 Iron 3 1341 Mean Difference (IV, Fixed, 95% CI) 0.30 [0.15, 0.45]
3.2 No iron 2 331 Mean Difference (IV, Fixed, 95% CI) 0.38 [0.12, 0.65]
4 Mean Hb at 12 weeks 4 1672 Mean Difference (IV, Random, 95% CI) 0.35 [0.06, 0.64]
4.1 Iron 3 1341 Mean Difference (IV, Random, 95% CI) 0.24 [0.08, 0.40]
4.2 No iron 2 331 Mean Difference (IV, Random, 95% CI) 0.57 [-0.10, 1.23]
Comparison 2. IPT in high versus low endemic areas
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All cause mortality plus hospital
admissions at 6 months
3 3160 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.71, 1.13]
1.1 High endemicity 2 1960 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.71, 1.19]
1.2 Low endemicity 1 1200 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.43, 1.44]
2 Children with anaemia at 12
weeks
4 2237 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.88, 1.07]
2.1 High endemicity 2 709 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.90, 1.15]
2.2 Low endemicity 2 1528 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.74, 1.07]
3 Mean change in Hb (baseline to
12 weeks)
4 1672 Mean Difference (IV, Fixed, 95% CI) 0.32 [0.19, 0.45]
3.1 High endemicity 2 641 Mean Difference (IV, Fixed, 95% CI) 0.35 [0.17, 0.53]
3.2 Low endemicity 2 1031 Mean Difference (IV, Fixed, 95% CI) 0.29 [0.10, 0.48]
4 Mean Hb at 12 weeks 4 1672 Mean Difference (IV, Random, 95% CI) 0.35 [0.06, 0.64]
4.1 High endemicity 2 641 Mean Difference (IV, Random, 95% CI) 0.44 [-0.03, 0.91]
4.2 Low endemicity 2 1031 Mean Difference (IV, Random, 95% CI) 0.20 [0.01, 0.40]
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Comparison 3. IPT plus Vitamin A and C versus IPT in the presence of iron
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Children with anaemia at 12
weeks
1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.75, 1.23]
2 Mean change in Hb (baseline to
12 weeks)
1 138 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.48, 0.48]
3 Mean Hb at 12 weeks 1 138 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.65, 0.45]
Analysis 1.1. Comparison 1 IPT versus placebo, Outcome 1 All-cause mortality plus hospital admissions at
6 months.
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 1 IPT versus placebo
Outcome: 1 All-cause mortality plus hospital admissions at 6 months
Study or subgroup IPT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Iron
Desai 2003 KEN (1) 6/135 2/139 1.5 % 3.09 [ 0.63, 15.04 ]
Bojang 2010 GMB (2) 18/600 23/600 17.7 % 0.78 [ 0.43, 1.44 ]
Subtotal (95% CI) 735 739 19.2 % 0.96 [ 0.56, 1.67 ]
Total events: 24 (IPT), 25 (Placebo)
Heterogeneity: Chi2 = 2.53, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.13 (P = 0.90)
2 No iron
Desai 2003 KEN (3) 1/136 4/136 3.1 % 0.25 [ 0.03, 2.21 ]
Phiri 2012 MWI (4) 91/706 101/708 77.7 % 0.90 [ 0.69, 1.18 ]
Subtotal (95% CI) 842 844 80.8 % 0.88 [ 0.68, 1.14 ]
Total events: 92 (IPT), 105 (Placebo)
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 1577 1583 100.0 % 0.90 [ 0.71, 1.13 ]
Total events: 116 (IPT), 130 (Placebo)
Heterogeneity: Chi2 = 3.86, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
0.01 0.1 1 10 100
Favours IPT Favours placebo
days to all children
six doses at 1 and 2 months post discharge.
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(1) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks. Iron given daily for 12 weeks to all participants.
(2) Bojang 2010: All children were treated for malaria (quinine and SP; if Hb <5g/dL transfusion); SP or placebo given monthly until end of transmission period. Iron given
daily for 28
(3) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks.
(4) Phiri 2012: All children received treatment for severe malarial anaemia (transfusion and quinine) as well as six doses of arthemether-lumefantrine (AL). IPT or placebo
group received
Analysis 1.2. Comparison 1 IPT versus placebo, Outcome 2 Children with anaemia at 12 weeks.
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 1 IPT versus placebo
Outcome: 2 Children with anaemia at 12 weeks
Study or subgroup IPT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Iron
Tomashek 2001 TNZ (1) 48/81 53/82 16.5 % 0.92 [ 0.72, 1.17 ]
Desai 2003 KEN (2) 56/135 61/139 18.9 % 0.95 [ 0.72, 1.24 ]
Verhoef 2002 KEN (3) 30/82 42/82 13.2 % 0.71 [ 0.50, 1.02 ]
Bojang 2010 GMB (4) 14/600 17/600 5.3 % 0.82 [ 0.41, 1.66 ]
Subtotal (95% CI) 898 903 53.9 % 0.87 [ 0.74, 1.02 ]
Total events: 148 (IPT), 173 (Placebo)
Heterogeneity: Chi2 = 1.75, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
2 No iron
Desai 2003 KEN (5) 100/136 89/136 27.9 % 1.12 [ 0.96, 1.32 ]
Verhoef 2002 KEN (6) 60/82 58/82 18.2 % 1.03 [ 0.85, 1.25 ]
Subtotal (95% CI) 218 218 46.1 % 1.09 [ 0.96, 1.23 ]
Total events: 160 (IPT), 147 (Placebo)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
Total (95% CI) 1116 1121 100.0 % 0.97 [ 0.88, 1.07 ]
Total events: 308 (IPT), 320 (Placebo)
Heterogeneity: Chi2 = 7.07, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Chi2 = 4.74, df = 1 (P = 0.03), I2 =79%
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(1) Tomashek 2001: IPT (SP monthly for three months) vs placebo; both groups recieved SP + mebendazole at baseline and folic acid plus iron three times a week
(2) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks. Iron given daily for 12 weeks to all participants.
(3) Verhoef 2002: IPT (SP) or placebo given monthly and iron twice per week for 12 weeks
(4) Bojang 2010: All children were treated for malaria (quinine and SP; if Hb <5g/dL transfusion); SP or placebo given monthly until end of transmission period. Iron given
daily for 28
(5) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks.
(6) Verhoef 2002: IPT (SP) or placebo given monthly
Analysis 1.3. Comparison 1 IPT versus placebo, Outcome 3 Mean change in Hb (baseline to 12 weeks).
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 1 IPT versus placebo
Outcome: 3 Mean change in Hb (baseline to 12 weeks)
Study or subgroup IPT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Iron
Tomashek 2001 TNZ (1) 73 3.5 (1.55) 77 3.6 (1.2) 8.6 % -0.10 [ -0.55, 0.35 ]
Desai 2003 KEN (2) 129 1.57 (1.12) 127 1.12 (1.02) 24.9 % 0.45 [ 0.19, 0.71 ]
Bojang 2010 GMB (3) 464 5.7 (1.54) 471 5.4 (1.6) 42.2 % 0.30 [ 0.10, 0.50 ]
Subtotal (95% CI) 666 675 75.7 % 0.30 [ 0.15, 0.45 ]
Heterogeneity: Chi2 = 4.35, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 3.96 (P = 0.000075)
2 No iron
Desai 2003 KEN (4) 127 0.74 (1.23) 108 0.32 (1.12) 18.9 % 0.42 [ 0.12, 0.72 ]
Cox 2013 GMB (5) 50 1.004 (1.19) 46 0.76 (1.59) 5.3 % 0.24 [ -0.32, 0.81 ]
Subtotal (95% CI) 177 154 24.3 % 0.38 [ 0.12, 0.65 ]
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0049)
Total (95% CI) 843 829 100.0 % 0.32 [ 0.19, 0.45 ]
Heterogeneity: Chi2 = 4.89, df = 4 (P = 0.30); I2 =18%
Test for overall effect: Z = 4.83 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
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(1) Tomashek 2001: IPT (SP monthly for three months) vs placebo; both groups recieved SP + mebendazole at baseline and folic acid plus iron three times a week
(2) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks. Iron given daily for 12 weeks to all participants.
(3) Bojang 2010: All children were treated for malaria (quinine and SP; if Hb <5g/dL transfusion); SP or placebo given monthly until end of transmission period. Iron given
daily for 28
(4) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks.
(5) Cox 2013: Chloroquine/placebo given weekly for 3 months. All children received malaria treatment at baseline
Analysis 1.4. Comparison 1 IPT versus placebo, Outcome 4 Mean Hb at 12 weeks.
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 1 IPT versus placebo
Outcome: 4 Mean Hb at 12 weeks
Study or subgroup IPT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Iron
Bojang 2010 GMB (1) 464 10.8 (1.7) 471 10.6 (1.8) 23.4 % 0.20 [ -0.02, 0.42 ]
Desai 2003 KEN (2) 129 11.05 (1.1) 127 10.7 (1) 22.4 % 0.35 [ 0.09, 0.61 ]
Tomashek 2001 TNZ (3) 73 10.2 (1.74) 77 10.2 (1.34) 15.0 % 0.0 [ -0.50, 0.50 ]
Subtotal (95% CI) 666 675 60.8 % 0.24 [ 0.08, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.71, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0037)
2 No iron
Cox 2013 GMB (4) 50 10.344 (0.96) 46 10.13 (1.02) 18.0 % 0.21 [ -0.18, 0.61 ]
Desai 2003 KEN (5) 127 10.8 (1.2) 108 9.91 (1.1) 21.2 % 0.89 [ 0.60, 1.18 ]
Subtotal (95% CI) 177 154 39.2 % 0.57 [ -0.10, 1.23 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 7.21, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.67 (P = 0.095)
Total (95% CI) 843 829 100.0 % 0.35 [ 0.06, 0.64 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 16.93, df = 4 (P = 0.002); I2 =76%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 0.89, df = 1 (P = 0.35), I2 =0.0%
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(1) Bojang 2010: All children were treated for malaria (quinine and SP; if Hb <5g/dL transfusion); SP or placebo given monthly until end of transmission period. Iron given
daily for 28
(2) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks. Iron given daily for 12 weeks to all participants.
(3) Tomashek 2001: IPT (SP monthly for three months) vs placebo; both groups recieved SP + mebendazole at baseline and folic acid plus iron three times a week
(4) Cox 2013: Chloroquine/placebo given weekly for 3 months. All children received malaria treatment at baseline
(5) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks.
Analysis 2.1. Comparison 2 IPT in high versus low endemic areas, Outcome 1 All cause mortality plus
hospital admissions at 6 months.
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 2 IPT in high versus low endemic areas
Outcome: 1 All cause mortality plus hospital admissions at 6 months
Study or subgroup IPT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High endemicity
Desai 2003 KEN (1) 6/135 2/139 1.5 % 3.09 [ 0.63, 15.04 ]
Desai 2003 KEN (2) 1/136 4/136 3.1 % 0.25 [ 0.03, 2.21 ]
Phiri 2012 MWI (3) 91/706 101/708 77.7 % 0.90 [ 0.69, 1.18 ]
Subtotal (95% CI) 977 983 82.3 % 0.92 [ 0.71, 1.19 ]
Total events: 98 (IPT), 107 (Placebo)
Heterogeneity: Chi2 = 3.64, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Low endemicity
Bojang 2010 GMB (4) 18/600 23/600 17.7 % 0.78 [ 0.43, 1.44 ]
Subtotal (95% CI) 600 600 17.7 % 0.78 [ 0.43, 1.44 ]
Total events: 18 (IPT), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 1577 1583 100.0 % 0.90 [ 0.71, 1.13 ]
Total events: 116 (IPT), 130 (Placebo)
Heterogeneity: Chi2 = 3.86, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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(1) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks. Iron given daily for 12 weeks to all participants.
(2) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks.
(3) Phiri 2012: All children received treatment for severe malarial anaemia (transfusion and quinine) as well as six doses of arthemether-lumefantrine (AL). IPT or placebo
group received
(4) Bojang 2010: All children were treated for malaria (quinine and SP; if Hb <5g/dL transfusion); SP or placebo given monthly until end of transmission period. Iron given
daily for 28
Analysis 2.2. Comparison 2 IPT in high versus low endemic areas, Outcome 2 Children with anaemia at 12
weeks.
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 2 IPT in high versus low endemic areas
Outcome: 2 Children with anaemia at 12 weeks
Study or subgroup IPT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High endemicity
Desai 2003 KEN (1) 56/135 61/139 18.9 % 0.95 [ 0.72, 1.24 ]
Desai 2003 KEN (2) 100/136 89/136 27.9 % 1.12 [ 0.96, 1.32 ]
Tomashek 2001 TNZ (3) 48/81 53/82 16.5 % 0.92 [ 0.72, 1.17 ]
Subtotal (95% CI) 352 357 63.3 % 1.02 [ 0.90, 1.15 ]
Total events: 204 (IPT), 203 (Placebo)
Heterogeneity: Chi2 = 2.51, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 0.26 (P = 0.79)
2 Low endemicity
Bojang 2010 GMB (4) 14/600 17/600 5.3 % 0.82 [ 0.41, 1.66 ]
Verhoef 2002 KEN (5) 60/82 58/82 18.2 % 1.03 [ 0.85, 1.25 ]
Verhoef 2002 KEN (6) 30/82 42/82 13.2 % 0.71 [ 0.50, 1.02 ]
Subtotal (95% CI) 764 764 36.7 % 0.89 [ 0.74, 1.07 ]
Total events: 104 (IPT), 117 (Placebo)
Heterogeneity: Chi2 = 3.92, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 1116 1121 100.0 % 0.97 [ 0.88, 1.07 ]
Total events: 308 (IPT), 320 (Placebo)
Heterogeneity: Chi2 = 7.07, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Chi2 = 1.43, df = 1 (P = 0.23), I2 =30%
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(1) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks. Iron given daily for 12 weeks to all participants.
(2) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks.
(3) Tomashek 2001: IPT (SP monthly for three months) vs placebo; both groups recieved SP + mebendazole at baseline and folic acid plus iron three times a week
(4) Bojang 2010: All children were treated for malaria (quinine and SP; if Hb <5g/dL transfusion); SP or placebo given monthly until end of transmission period. Iron given
daily for 28
(5) Verhoef 2002: IPT (SP) or placebo given monthly
(6) Verhoef 2002: IPT (SP) or placebo given monthly and iron twice per week for 12 weeks
Analysis 2.3. Comparison 2 IPT in high versus low endemic areas, Outcome 3 Mean change in Hb (baseline
to 12 weeks).
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 2 IPT in high versus low endemic areas
Outcome: 3 Mean change in Hb (baseline to 12 weeks)
Study or subgroup IPT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High endemicity
Desai 2003 KEN (1) 129 1.57 (1.12) 127 1.12 (1.02) 24.9 % 0.45 [ 0.19, 0.71 ]
Desai 2003 KEN (2) 127 0.74 (1.23) 108 0.32 (1.12) 18.9 % 0.42 [ 0.12, 0.72 ]
Tomashek 2001 TNZ (3) 73 3.5 (1.55) 77 3.6 (1.2) 8.6 % -0.10 [ -0.55, 0.35 ]
Subtotal (95% CI) 329 312 52.4 % 0.35 [ 0.17, 0.53 ]
Heterogeneity: Chi2 = 4.69, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 3.78 (P = 0.00016)
2 Low endemicity
Bojang 2010 GMB (4) 464 5.7 (1.54) 471 5.4 (1.6) 42.2 % 0.30 [ 0.10, 0.50 ]
Cox 2013 GMB (5) 50 1.004 (1.19) 46 0.76 (1.59) 5.3 % 0.24 [ -0.32, 0.81 ]
Subtotal (95% CI) 514 517 47.6 % 0.29 [ 0.10, 0.48 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0024)
Total (95% CI) 843 829 100.0 % 0.32 [ 0.19, 0.45 ]
Heterogeneity: Chi2 = 4.89, df = 4 (P = 0.30); I2 =18%
Test for overall effect: Z = 4.83 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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(1) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks. Iron given daily for 12 weeks to all participants.
(2) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks.
(3) Tomashek 2001: IPT (SP monthly for three months) vs placebo; both groups recieved SP + mebendazole at baseline and folic acid plus iron three times a week
(4) Bojang 2010: All children were treated for malaria (quinine and SP; if Hb <5g/dL transfusion); SP or placebo given monthly until end of transmission period. Iron given
daily for 28
(5) Cox 2013: Chloroquine/placebo given weekly for 3 months. All children received malaria treatment at baseline
Analysis 2.4. Comparison 2 IPT in high versus low endemic areas, Outcome 4 Mean Hb at 12 weeks.
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 2 IPT in high versus low endemic areas
Outcome: 4 Mean Hb at 12 weeks
Study or subgroup IPT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High endemicity
Desai 2003 KEN (1) 127 10.8 (1.2) 108 9.91 (1.1) 21.2 % 0.89 [ 0.60, 1.18 ]
Desai 2003 KEN (2) 129 11.05 (1.1) 127 10.7 (1) 22.4 % 0.35 [ 0.09, 0.61 ]
Tomashek 2001 TNZ (3) 73 10.2 (1.74) 77 10.2 (1.34) 15.0 % 0.0 [ -0.50, 0.50 ]
Subtotal (95% CI) 329 312 58.6 % 0.44 [ -0.03, 0.91 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 11.90, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 1.84 (P = 0.065)
2 Low endemicity
Bojang 2010 GMB (4) 464 10.8 (1.7) 471 10.6 (1.8) 23.4 % 0.20 [ -0.02, 0.42 ]
Cox 2013 GMB (5) 50 10.344 (0.96) 46 10.13 (1.02) 18.0 % 0.21 [ -0.18, 0.61 ]
Subtotal (95% CI) 514 517 41.4 % 0.20 [ 0.01, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.042)
Total (95% CI) 843 829 100.0 % 0.35 [ 0.06, 0.64 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 16.93, df = 4 (P = 0.002); I2 =76%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 0.85, df = 1 (P = 0.36), I2 =0.0%
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(1) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks.
(2) Desai 2003: All participants received baseline dose of SP at enrollement; SP or placebo given at 4 and 8 weeks. Iron given daily for 12 weeks to all participants.
(3) Tomashek 2001: IPT (SP monthly for three months) vs placebo; both groups recieved SP + mebendazole at baseline and folic acid plus iron three times a week
(4) Bojang 2010: All children were treated for malaria (quinine and SP; if Hb <5g/dL transfusion); SP or placebo given monthly until end of transmission period. Iron given
daily for 28
(5) Cox 2013: Chloroquine/placebo given weekly for 3 months. All children received malaria treatment at baseline
Analysis 3.1. Comparison 3 IPT plus Vitamin A and C versus IPT in the presence of iron, Outcome 1
Children with anaemia at 12 weeks.
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 3 IPT plus Vitamin A and C versus IPT in the presence of iron
Outcome: 1 Children with anaemia at 12 weeks
Study or subgroup IPT+VAC IPT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tomashek 2001 TNZ 41/65 48/73 100.0 % 0.96 [ 0.75, 1.23 ]
Total (95% CI) 65 73 100.0 % 0.96 [ 0.75, 1.23 ]
Total events: 41 (IPT+VAC), 48 (IPT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 IPT plus Vitamin A and C versus IPT in the presence of iron, Outcome 2 Mean
change in Hb (baseline to 12 weeks).
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 3 IPT plus Vitamin A and C versus IPT in the presence of iron
Outcome: 2 Mean change in Hb (baseline to 12 weeks)
Study or subgroup IPT+VAC IPT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tomashek 2001 TNZ 65 3.5 (1.4) 73 3.5 (1.49) 100.0 % 0.0 [ -0.48, 0.48 ]
Total (95% CI) 65 73 100.0 % 0.0 [ -0.48, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 IPT plus Vitamin A and C versus IPT in the presence of iron, Outcome 3 Mean
Hb at 12 weeks.
Review: Intermittent preventive antimalarial treatment for children with anaemia
Comparison: 3 IPT plus Vitamin A and C versus IPT in the presence of iron
Outcome: 3 Mean Hb at 12 weeks
Study or subgroup IPT+VAC IPT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tomashek 2001 TNZ 65 10.1 (1.6) 73 10.2 (1.7) 100.0 % -0.10 [ -0.65, 0.45 ]
Total (95% CI) 65 73 100.0 % -0.10 [ -0.65, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Summary of trial characteristics
Trial Bojang 2010
GMB
Cox 2013 GMB Desai 2003KEN Phiri 2012MWI Verhoef 2002
KEN
Tomashek 2001
TNZ
Sample size (n
randomized)
1200 96 554 1431 328 238
Country The Gambia
(Banjul)
The Gambia Kenya (Western
Kenya)
Malawi (south-
ern Malawi)
Kenya (Eastern
province)
Tanzania
(Kigoma region)
Endemicity low* low* high* high* low* moderate/
high (50% para-
sitaemia)**
Age 3 months to 9
years
12 to 72 months 2 to 36 months 4 to 59 months 2 to 36 months 6 to 59 months
Anaemia Hb < 7 g/dL Hb 69 to 110 g/
L
Hb7.0 to 10.9 g/
dL
All
children treated
for severe malar-
ial anaemia with
transfusion and
completed the
course of intra-
venous quinine
with subsequent
Hb > 5g/dL
Hb 60 to 110 g/
L
Hb 5.0 to 8.0 g/
dL
Malaria Not criteria for
inclusion. Chil-
dren with
malaria were
treated
Uncomplicated
malaria
No malaria
(apara-
sitaemic) or par-
asite counts <
20,000parasites/
mm3
No clinical
malaria
Not described as
part of eligibility
Recruitment Hospital or
OPD admission
Active and pas-
sive case find-
ing of children in
community
Community:
resident children
screened
Hospital admis-
sions
Community:
randomly
selected
Health
care worker diag-
nosed chil-
dren with clini-
cal anaemia and
referred them to
the trial
Trial interven-
tion
1. IPT (SP)
2. Placebo
1. IPT (CQ)
2. Placebo
1. IPT (SP) +
iron
2. IPT (SP) +
iron placebo
3. Iron + IPT
placebo
4. Iron
placebo + IPT
placebo
1. IPT(post
discharge): AL
2. Placebo
1. IPT (SP) +
iron
2. IPT (SP) +
iron placebo
3. Iron + IPT
placebo
4. Iron
placebo + IPT
placebo
1. Vitamin
placebo 3X per
week
2. Vitamin
placebo + IPT
(SP)
3. VAC + IPT
(SP)
Iron and other
supplementa-
tion during trial
Yes: oral iron for
28 days
No No - part of trial
intervention
Not reported No - part of trial
intervention
Yes: Iron
and folic acid for
47Intermittent preventive antimalarial treatment for children with anaemia (Review)
Copyright © 2015 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 1. Summary of trial characteristics (Continued)
period (all par-
ticipants)
12 weeks
Baseline treat-
ment for all par-
ticipants
Some were
treated with qui-
nine and SP or
CQ and SP. Not
all children
Either CQ and
SP or AL
Single dose of SP 3 day course of
AL
in hospital (6
doses)
None Single dose of
SP; mebendazole
for participants >
12 months
*endemicity derived from the Malaria Atlas Project (Gething 2011).
**as reported in the trial (Tomashek 2001 TNZ).
Abbreviations:
Hb: Haemoglobin
OPD: Out patient department
IPT: Intermittent preventive treatment
SP:Sulfadoxine-pyrimethamine
CQ: Chloroquine
AL: Arthemeter-lumefantrine
VAC: Vitamin A and C
Table 2. Summary of outcomes reported in trials
Outcomes Trial Bojang 2010
GMB
Cox 2013
GMB
Desai 2003
KEN
Phiri 2012
MWI
Verhoef 2002
KEN
Tomashek
2001 TNZ
Haematolog-
ical outcomes
Mean Hb at
end of follow-
up
MeanHb level
at endof trans-
mission
period
- Hb concentra-
tion (mea-
sured in g/dL)
- Hb concentra-
tion at the end
of follow-up
(12 weeks)*
Mean Hb
Mean
change of Hb
from baseline
to follow-up
- Mean change
of Hb from
baseline to fol-
low-up
- - - -
Children
with anaemia
at follow-up
Proportion of
children with
mod-
erate or se-
vere anaemia
at the end of
the transmis-
sion period*
- Hematologi-
cal re-
covery (Hb ≥
11g/dL before
or at week 12)
Severe
anaemia (Hb
< 7 g/dL be-
fore or at week
12)
- Anaemia (Hb
< 11.0 g/dL)
Prevalence of
anaemia (Hb
< 11.0 g/dL)
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Table 2. Summary of outcomes reported in trials (Continued)
Other - Change in ery-
thropoietic re-
sponse
Hb change
from baseline
to follow-up
in two placebo
arms to inves-
tigate the ef-
fect of anti-
malarial ther-
apy
MCV (mea-
sured in fL)
sTfR concen-
tration (mea-
sured in µg/
mL)
- Iron defi-
ciency (serum
fer-
ritin concen-
tration < 12
µg/L)
Mean TfR
level
Prevalence
of iron defi-
ciency (TfR <
8.5 µg/mL)
Malaria out-
comes
Clinical
malaria
Clini-
cal episodes of
malaria during
the surveil-
lance period
- Clinical
malaria (axil-
lary tempera-
ture 37.5 with
co-ex-
isting malaria
parasitaemia)
- Proportion of
children with
at least
onemalaria at-
tack (defined
as presence of
fever, that
is temperature
≥ 37.5°C, and
a positive dip-
stick result)*
-
Malaria para-
sitaemia
Preva-
lence of par-
asitaemia and
splenomegaly
Prevalence of
submicro-
scopic malaria
parasitaemia
Prevalence of
malaria para-
sitaemia
Parasite den-
sity (parasites/
mm3)
- - -
Hospital ad-
missions
or clinic vis-
its related to
malaria
- - - Hospital re-
admission be-
cause of all-
cause severe
anaemia or se-
vere malaria
Clinic
visits because
of microscopi-
cally con-
firmed non-
severe malaria
- -
Other - - - - Time to first
occurrence of
malaria attack
-
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Table 2. Summary of outcomes reported in trials (Continued)
All-cause mortality and hos-
pital admission
- - - Compos-
ite outcome of
all-cause mor-
tality and hos-
pital readmis-
sion because
of all-cause se-
vere anaemia
or
severe malaria
between 1 and
6 months*
All-cause hos-
pital
admission
All-causemor-
tality
- -
Visits to healthcare facilities Outpatient at-
tendance
- Clinic vis-
its (incidence,
number of
episodes)
All-cause sick
child clinic
visits
- -
Other Nutri-
tional status at
the end oft he
transmission
period
Compliance
with treat-
ment regimen
Change in uri-
nary
neopterin
- - Adverse drug
reactions
-
*indicates primary outcomes
Abbreviations:
Hb: haemoglobin
TfR: transferrin receptor
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A P P E N D I C E S
Appendix 1. Search strategy
Search set CIDG SR1 CENTRAL MEDLINE2 EMBASE2 LILACS2
1 Anemia OR anaemia Anemia (MeSH, ti, ab
)
Anemia (MeSH, ti, ab
) OR anaemia (ti, ab)
Anemia (Emtree, ti,
ab ) OR anaemia (ti,
ab)
Anemia OR anaemia
2 malaria Malaria (MeSH, ti,
ab)
Malaria (MeSH, ti,
ab)
Malaria (Emtree, ti,
ab)
malaria
3 Child* OR infant* 1 OR 2 1 OR 2 1 OR 2 Child$ OR infant$
4 (Intermittent Preven-
tive treatment) OR
IPT*
Child* OR infant*(ti,
ab)
Child* OR infant*(ti,
ab)
Child* OR infant*(ti,
ab)
(Intermittent Preven-
tive treatment) OR
IPT$
5 1 or 2 3 and 4 3 and 4 3 and 4 1 or 2
6 3 and 4 and 5 (Intermittent preven-
tive treatment) ti, ab
(Intermittent preven-
tive treatment) ti, ab
(Intermittent preven-
tive treatment) ti, ab
3 and 4 and 5
7 - IPT*(ti,ab) IPT*(ti,ab) IPT*(ti,ab)
8 - 6 or 7 6 or 7 6 or 7
9 - 5 and 8 5 and 8 5 and 8
10 - - - -
1Cochrane Infectious Diseases Group Specialized Register.
2Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre
2011).
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. We planned to include only children under the age of five (as stated in protocol), but when screening the studies, we noticed that
some of them included children up to the age of nine years and we thus decided to include all children.
2. In the protocol, we prespecified the following outcomes:
Primary outcomes:
• Mean Hb at follow-up (g/dL)
• Mean change in Hb from baseline at follow-up
Secondary outcomes:
• Complete recovery from severe anaemia (Hb > 5 g/dL)
• Complete recovery from moderate anaemia (Hb > 8 g/dL)
• Blood transfusions
• All-cause mortality
• Admission due to severe anaemia
During our fellowship (MK and AR) at the editorial base of the Cochrane Infectious Diseases Group (CIDG) in Liverpool, we discussed
these outcomes with some of the CIDG editors. We also consulted Higgins 2011 and agreed that mortality and hospital admission
would be more meaningful outcomes to clinicians and decision-makers, than mean Hb levels. We thus changed the primary and
secondary outcomes to the following:
Primary outcomes:
• All-cause mortality and hospital admission
Secondary outcomes:
• Anaemia at follow-up (Hb < 11 g/dL)
• Mean change in Hb (g/dL) from baseline to follow-up
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• Mean Hb at follow-up (g/dL)
3. We planned to perform the following subgroup analyses:
• IPTi versus IPTc
• Additional interventions to treat anaemia (such as, hematinics or folic acid)
• The use of LLINs or not
Due to the lack of heterogeneity and the limited amount of included trials, we only performed the following subgroup analyses:
• Additional interventions to treat anaemia (such as, hematinics or folic acid)
• Hospital recruitment versus community recruitment
4. Due to the limited number of trials included in the analyses, we did not do sensitivity analyses.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anemia [blood; etiology; ∗prevention & control]; Antimalarials [∗therapeutic use]; Endemic Diseases [∗prevention & control];
Hemoglobin A [metabolism]; Iron Compounds [administration & dosage]; Malaria [complications; ∗prevention & control]; Random-
ized Controlled Trials as Topic
MeSH check words
Child, Preschool; Humans; Infant; Infant, Newborn
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